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1 Introduction and Objectives 
1.1 Introduction 
Orthopaedic trauma is a global problem and constitutes a significant source of 
morbidity and mortality for all ages and both genders [1]. This health detriment 
is mainly caused by violence or accidental injury and affects every nation in the 
world [2]. Various forms of traumatic injury lead to long-term consequences for 
individuals as well as for the society, making up twelve percent of the gobal 
disease burden [1, 2]. Trauma-related fractures and healing of bone defects still 
provide a clinical problem in orthopaedic surgery [3]. Cases with fractures and 
delayed healing or non-unions may result in a number of surgeries and 
contribute to increased health care costs [4]. Autologous bone graft that may 
enhance bone healing processes is not always available in sufficient quantity to 
enable treatment of these kinds of fractures [5]. The limited amount of graft 
material and the associated morbidity of the graft harvested procedure are well-
known drawbacks of this treatment despite which it represents the current gold 
standard technique [6]. As an alternative to autologous bone used in fracture 
treatment, various synthetic materials such as metals, ceramics, glasses, 
polymers and composites are frequently used either as a bone substitute or as a 
bone graft extender. In particular, ceramics based on calcium phosphates have a 
long history of successful orthopaedic applications such as bone void filling and 
augmentation [7]. These are attractive as they contain calcium which is also 
present in the mineral phase of bone. Over the last decades, they have been 
widely used and have proven to have excellent in vivo biocompatibility and bone 
repair abilities when used as synthetic osteoconductive scaffolds [8-12].  
In addition to the above mentioned causes for orthopaedic trauma, fractures can 
also be related to certain musculoskeletal diseases such as osteoporosis. This 
particular metabolic bone disease is characterized by decreased bone mineral 
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density. Many orthopaedic patients, predominantly postmenopausal women, are 
affected by osteoporosis resulting in an increased risk of bone fractures [13]. For 
the year 2000, nine million new osteoporotic fractures were estimated world-
wide [14]. The application of standard implants for fracture fixation of 
osteoporotic bone is limited due to poor bone quality and fixation failures are 
more likely to occur [15, 16]. Various drugs and pharmaceutical products have 
been developed for the treatment and prevention of osteoporosis. 
Bisphosphonates, a major class of antiporotic drugs, has been shown to be 
among the most effective inhibitors of bone resorption [17]. 
During the last decade, numerous studies have established a new field of 
research focussing on and development of a combination of active bone drugs 
and medical devices for use in an osteoporotic bone environment. Calcium 
phosphates have the ability to incorporate several chemical substances on their 
surfaces, for instance proteins, antibiotics or anti-tumor agents [18-20]. Based 
on clinical needs, bioceramics may be loaded by adsorption with active agents to 
offer the potential for innovative drug delivery systems. A candidate bone 
substitute material must have the ability to incorporate pharmaceuticals in a 
target load and to release it appropriately to the surrounding bone tissue. 
Moreover, there is an increasing interest in an additional local pharmacological 
treatment to generate an added clinical value [20-26]. Many research activities 
focus on maximizing controlled drug release at specific bone sites and 
maintaining a prolonged drug concentration level whilst avoiding 
pharmacological side effects [27].  
A combination product which offers an osteoconductive matrix for new bone 
growth and is also a carrier for local controlled bisphosphonate delivery, could 
be very attractive in the treatment of osteoporotic fractures. In this, the 
implantation of bone substitute materials releasing the bisphosphonate 
zoledronic acid (ZOL) would potentially both, reduce bone resorption and 
maintain bone mass [28, 29]. 
Introduction and Objectives 
3 
1.2 Objectives 
There is growing interest in combining the bisphosphonate zoledronic acid 
(ZOL) with orthopaedic implants with the goal of improving bone quality at the 
implant-bone interface and reducing the risk of implant migration and failure.  
The first objective of the present thesis was to evaluate the feasibility of 
different calcium phosphate based bioceramics as potential drug carriers. The 
properties of the materials were tested by using a number of physico-chemical 
methods. The second aim was to develop a straight forward method for reliably 
and repeatably combining ZOL with bone substitute materials using a short-term 
dipping technique which could be promising for clinical application in terms of 
loading bone substitutes directly prior or during surgery with defined drug 
content. The third goal was to evaluate the materials with respect to their ZOL 
loading capacity in a time and concentration dependent manner. The fourth aim 
was to assess the bone substitutes as release systems for ZOL in an in vitro 
approach. Furthermore, ZOL stability under different storage conditions, 
cytotoxicity of ZOL with a cell line and a characterisation of modified cement 
formulations had to be performed to design an implant applicable for an animal 
model. Dependent on the findings, the final objective was to test the short-term 
in vivo efficacy of a ZOL loaded bone cement plug. For this purpose, a bone 
defect model in the proximal tibia of rats was used. An in vivo study was 
conducted to gain experience on how to influence bone-implant contact, bone 
regeneration, and bone area around the implant in cancellous bone. The 
interpretation of a drug loading and releasing concept using a preshaped bone 
cement plug was supported by performing quantitative polymerase chain 
reaction (qPCR) and histological analysis.  
The present work is an additional contribution to the knowledge of how ZOL 
interacts with different forms of calcium phosphate and what effects ZOL could 
have in an in vivo animal model.  
Theoretical background 
4 
2 Theoretical background 
2.1 Bone 
Bone is a complex and dynamic tissue with several functions such as locomotion 
of the human body and self maintenance of its intrinsic structure through 
continuous remodelling [30]. Bones act as an organ responsible for the mineral 
balance of the body which is controlled by hormones [31]. It acts as a reservoir 
for calcium and phosphate in the preservation of normal mineral homeostasis 
[32]. Additionally, bone allows elasticity and rigidity to withstand bending, 
torsion and combinations of forces without fracturing and provides mechanical 
support for joints, tendons, and ligaments [33]. Furthermore, bone protects vital 
organs from damage [34]. A typical structure of bone is shown in Figure 2.1. 
Bone is divided into cortical and trabecular structures and each of these forms 
differ in respect of cellular content, metabolic rate and remodelling process [35].  
Cortical bone makes up the majority of bone with approximately 80% of skeletal 
bone mass. It is denser than trabecular bone with a low surface area to volume 
ratio and is mainly present in the shafts of long bones. It also forms the outer 
layer of all bones [32]. This type of bone is formed by the Haversian system 
which consists of osteons, forming concentric lamellae of bone tissue 
surrounding a central canal containing blood vessels [36]. Approximately 20% 
of skeletal bone mass consists of trabecular or cancellous bone. It offers porous 
structures and has a lower density than cortical bone [30]. Cancellous bone is 
located in the centre of flat bones, vertebrae, and both at the centre and the ends 
of long bones. This bone structure is characterized by an interconnecting 
meshwork of defined patterns consisting of a large number of bony trabecular 
cells combined into a three-dimensional matrix with a large surface area [34, 37, 
38]. A high metabolic turnover and concentration of bone cells is specific for 
trabecular bone [39]. Caused by an increased surface area, the remodelling of 
trabecular bone proceeds more rapidly compared to cortical bone [30]. 
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Figure 2.1: Schematic drawing of bone structure modified from Rahn [40]. 
2.1.1 Composition 
Bone is composed of a unique combination of intercellular calcified material 
(bone matrix) and bone cells (Figure 2.2). Bone matrix is a composite material 
consisting of organic and inorganic components which is initially deposited by 
osteoblasts as unmineralized precursor substance (osteoid) [41]. The organic 
component usually makes up approximately 20% of the wet weight of bone and 
mainly consists of collagen and other non-collagenous proteins [42]. Collagen 
fibres are the major structural component of bone matrix, whereby the majority 
is type I [34]. The distribution of collagen and mineral provides bone with its 
ability to balance its flexibility and stiffness requirements [43]. The non-
collageneous macromolecules are important for controlling the attachment of 
bone cells to the matrix and regulating cell activity associated with the 
biomineralization process and remodelling in bone tissue [44]. Some of these 
substances (e.g. osteocalcin) are specific to bone. Non-specific macromolecules 
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(e.g. osteopontin, fibronectin and growth factors) are also present in other 
connective tissues [45]. The inorganic component contributes approximately 
70% of the wet weight of bone and serves as a reservoir storing approximately 
99% of total body calcium, 85% of phosphorus and 40-60% of body´s sodium 
and magnesium [34]. The mineralized components give strength and rigidity and 
fulfill the main mechanical support function within the human body. They 
consist of a mineral hydroxyapatite phase deposited in an organic matrix [34]. 
The stability of the skeleton to withstand pressure, tension, bending, and torsion, 
is based upon inclusion of inorganic components in the organic intercellular 
matrix [39]. The main component is hydroxyapatite, but also fluoroapatite, 
carbonated apatite, calcium carbonate, and magnesium carbonate are 
components in the mineral phase of bone [46]. The basic composition of bone is 
the same for all bones, but the components of the bone types are combined 
differently to form cortical or trabecular structures. 
 
 
Figure 2.2: Overview of the main bone composition. 
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2.1.2 Bone cells 
In human bone, different cell types can be identified (Figure 2.2). Bone tissue 
principially contains bone resorption cells (osteoclasts) and bone formation cells 
(including osteoblasts, osteocytes, bone lining cells and osteoprogenitor cells) 
[41]. The extracellular materials providing a matrix for these cells are organic 
material (e.g. collagen), inorganic material (e.g. minerals like calcium and 
phosphate), and water [34].  
Bone resorption processes and resorption of bone substitute materials are 
mediated by osteoclasts which are differentiated from hematopoietic stem cells 
of the monocyte-macrophage lineage in the bone marrow [47]. The 
differentiation is regulated by cytokines and hormones to activate remodelling 
processes or increase calcium and phosphate concentrations in the blood which 
is important for calcium and phosphate homeostasis [48]. Osteoclasts are large 
multinucleated cells and responsible for the absorption and removal of bone 
[49]. Attached to the bone surface, the osteoclasts create an acidic environment 
and bone tissue is dissolved by proteinase and enzyme activity to break down 
bone matrix effectively [50].  
Osteoblasts are responsible for bone formation processes of organic matrix and 
osteogenesis [51]. These cells are differentiated from mesenchymal stem cells. 
The differentiation is controlled by many cytokines and can be divided into 
several stages (proliferation, extracellular matrix deposition, matrix maturation 
and mineralisation) [52]. The osteoblast synthesises and secretes collagen and 
non-collagenous proteins that comprise the organic matrix of bone and 
subsequently mineralise the bone matrix [53]. Osteoblasts express high levels of 
alkaline phosphatase (ALP), a serum marker of bone formation [54]. Some 
osteoblasts disappear through programmed cell death (apoptosis), whereas 
others differentiate into flat cells lining the bone surface (bone lining cells) or 
become osteocytes surrounded by the bone matrix in small lacunae [34, 55].  
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Both lining cells and osteocytes play an important role in the regulatory process 
of maintaining bone. Bone lining cells mediate bone turnover by activation of 
remodelling processes by secreting enzymes [34].  
Osteocytes are characterized by long cell processes which form a complex 
network throughout the bone matrix [56]. These cells are trapped within the 
bone matrix during the process of bone formation and communicate with 
osteoblasts and bone lining cells at the bone surface [57]. They express a variety 
of molecules which make them respond to both, mechanical and hormonal 
stimuli.  
2.1.3 Bone modelling and remodelling 
Active bone tissue is able to modulate structures and mass in response to 
changing requirements. Under physiological conditions, there is a balance 
between bone-resorbing and bone-forming events. These processes are realized 
by many cell activities, including bone repair, growth, modelling and 
remodelling [41]. A higher metabolic bone turnover and remodelling rate take 
place in cancellous bone (approximately 30% per year) as compared to cortical 
bone (approximately 3% per year) [39, 58]. 
Bone modelling involves activation and isolated bone resorption or formation. 
The process of bone formation and resorption during modelling does not happen 
at the same location. Modelling primarily occurs during bone growth and 
usually declines in adults. Stimuli for bone modelling processes in adults are 
increased mechanical loading, administration of parathydroid hormone (PTH) 
and specific drugs [31]. Bone modelling is a process to add or remove bone 
tissue from an existing bone surface to modify bone geometry. It leads to 
changes in the size and shape of bone. This is achieved by uncoupled actions of 
osteoblasts and osteoclasts. Remodelling of the human bone matrix is a 
physiological process of bone reconstruction where parts of bone are replaced 
by new bone. It occurs permanently and involves coordinated actions of 
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osteoblasts and osteoclasts. These cells build basic multicellular units (BMUs) 
which remodel bone by activation, resorption, and formation processes. Bone 
remodelling is necessary to maintain calcium homeostasis and to repair damage 
in bone. In the BMU, osteoclastic bone resorption initiates osteoblastic bone 
formation [59]. The general bone remodelling cycle by a BMU is schematically 
shown in Figure 2.3. A stimulus activates osteoclastic precursors to differentiate 
into multinucleated osteoclasts (cutting cone). Osteoclastic cells bind to the bone 
surface and resorb bone. Bone resorption involves dissolution of crystalline 
calcium phosphates and degradation of collagen in the extra cellular resorption 
lacunae with the secretion of acids and enzymes by osteoclasts [50]. Following 
behind the osteoclasts, osteoblasts deposit layers of osteoid (unmineralized bone 
matrix). Osteoblasts always follow osteoclasts in BMU. The resorption and 
formation processes are coupled. The organic components of the matrix are then 
hydrolysed and osteoblasts are responsible for bone matrix formation and 
differentiate afterwards into osteocytes and bone lining cells [60]. 
Many diseases are caused as a result of abnormalities in bone remodelling which 
compromise the architecture, structure, and mechanical strength leading to 
clinical symptoms [17]. Consequently, there is a growing interest in defining the 
molecular mechanism by which bone remodelling is regulated [53].  
 
 
Figure 2.3: Bone remodelling process by a BMU described by Canalis et al. 
[60]. 
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2.1.4 Fracture healing 
A bone fracture is a break in the normal continuity of bone. When a fracture 
occurs, the bone, periosteum or surrounding tissues, like muscles, nerves or 
blood vessels, may be damaged or destroyed. The process of fracture healing is 
a complex cascade of specific events on a cellular and molecular level that 
ideally ends in complete structural and functional restoration of the involved 
bone [36]. Many different molecules and cells are involved, including 
inflammatory cytokines, growth factors, antioxidants, osteoclasts, osteoblasts, 
hormones, amino acids, and other nutrients [61]. Permanent bone remodelling 
provides a mechanism for healing and regeneration of damaged bone tissue [62]. 
This property is initiated in response to injury and healing of bone around and 
within implants [63]. Multiple factors influence the molecular mechanism that 
regulates bone tissue formation during bone repair [61]. Bone repair is typically 
divided into direct or primary and indirect or secondary fracture healing [62].  
Primary or direct fracture healing (intramembranous ossification) is described 
as the basic principle of fracture healing and occurs when fracture surfaces are 
rigidly held in contact. This type of healing is only possible under absolutely 
stable conditions and is characterized by the complete absence of a fracture 
callus [62]. In this situation, intramembranous ossification, bone formation, and 
the osteoid are directly effected by mesemchymal tissue [36]. Osteoclasts cross 
fracture sites whereby reestablishing new Haversian systems to form the cutting 
cone. Therefore, they provide pathways for the penetration of blood vessels [64]. 
Many fractures heal when micromotion between the fracture surfaces occurs 
[65]. If the construct is extremely rigid, there is no stimulus for healing. In 
practice the primary or direct fracture type is the rarest [36]. 
Secondary or indirect fracture healing (chondral ossification) is characterized by 
callus formation which is subsequently replaced by lamellar bone. It is found in 
less rigid, more flexible fixation that allows a certain amount of micromotion in 
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a wider fracture gap. This type of healing benefits from micromotion [36]. It is a 
complex process that involves the formation of a bridging callus of cartilage, 
bone and connective tissue cells, restoring the normal bone structure. In this 
situation, an interaction between bone forming (osteoblasts), bone resorbing 
(osteoclasts) cells and the influence of different growth factors, cytokines, and 
hormones in the formation of fracture callus occurs [62]. 
Secondary fracture healing is typically characterized by different overlapping 
stages, such as an early initial inflammatory response (heamatoma, 
inflammation, angiogenesis), a repair phase (cartilaginous callus formation and 
replacement of callus by lamellar bone), and a late bone remodelling phase [36]. 
These phases take place in the bone marrow, cortex, periosteum, and external 
soft tissues and they can overlap in time [62, 66]. A fracture can lead to damage 
of cortical and cancellous bone, bone marrow, endosteum, periosteum, and 
adjacent soft tissues. During the inflammatory phase, the hematoma is invaded 
and replaced by callus. Fracture healing is not homogenous within the callus. A 
callus consists of fibrovascular tissue in which abundant amounts of collagen 
fibers and woven bone matrix are laid down. The main zones are the medullary 
canal, the area between the cortices, the subperiosteal layer, and the surrounding 
soft tissue [61]. The fibrous callus (soft callus) within the fracture gap (cortical 
and medullary callus) creates bone by endochondral ossification. Membranous 
ossification is found in the external callus, far from the fracture site (hard 
callus). It is a result of direct osteoblast activity which forms both compact and 
trabecular bone directly without first forming cartilage. 
Within the early inflammatory phase a blood clot (heamatoma) is formed 
between the bone ends (Figure 2.4 a). Without an inflammatory process, bone 
will not heal. An inhibition of the cyclo-oxygenase pathway appears to inhibit 
bone formation [67]. The heamatoma itself is a source of signalling molecules 
for macrophages and chondroblast precursors which are important for the 
regulation of cell differentiation and angiogenesis [62, 68]. Inflammatory cells 
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secrete growth factors and cytokines which have chemotactic effects on other 
inflammatory cells and osteoblast precursors [69, 70]. The major signalling 
molecules in the cascade are interleukin 1 (IL-1), interleukin 6 (IL-6) [69], 
transforming growth factor b (TGF b) [71], insulin-like growth factor (IGF) 
[72], fibroblast growth factor (FGF) [73], platelet-derived growth factor (PDGF) 
[74], and bone morphogenetic proteins (BMPs) [67]. Granulocytes, mast cells 
and monocytes infiltrate locally. In addition, pluripotent stem cells of 
mesenchymal origin as precursors of osteoblasts migrate into the fracture gap. 
Within this time period, granulation tissue and new blood vessels rebuild under 
the influence of growth factors. Fibroblasts, collagen type I, capillaries, and 
initial mineral deposits are the main components of this granulation tissue and 
replace the fracture hematoma by fibrocartilaginous callus (Figure 2.4 b). 
During the reparative phase, the blood clot is replaced by fibrovascular tissue 
which lays down the collagen fibres and the matrix which will later become 
mineralised to form the woven bone of the primary callus (Figure 2.4 c) [36]. 
Proliferation and differentiation of mesenchymal and osteoprogenitor cells into 
chondroblasts and osteoblasts lead to vascularized granulation tissue and fibrous 
tissue with the production of extracellular matrix and collagen fibres [75]. 
Subsequently, these cells begin to form cartilage and woven bone to increase the 
mechanical stability of the fracture site (chondrogenesis). To promote 
osteoblastic proliferation, macrophages secrete proteins such as osteocalcin and 
BMPs. BMUs are formed and break down damaged bone. They are responsible 
for newly formed woven bone and a process of increased mineralization occurs. 
The remodelling phase of fracture healing is long-lasting and can take several 
years (Figure 2.4 d). Through this process, unoriented woven bone is replaced 
by mature lamellar bone, which is characterized by a dense structure of osteons, 
i.e. central Haversian canals with concentric layers of surrounding bone. Under 
ideal circumstances, the original tissue and its function are almost completely 
restored [36]. 
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Figure 2.4: Overlapping stages of secondary fracture healing: hematoma 
formation (a), fibrocartilaginous callus formation (b), bony 
callus formation (c) and bone remodelling (d). 
Differences in fracture healing processes between humans and animals pose a 
limitation on preclinical research. Fracture healing rates in rats, for example are 
about twice that in humans [61]. The main cellular and molecular processes of 
fracture healing in rodents are described by Einhorn [62]. Phillips describes the 
time period of fracture healing in rats as follows [61]. Briefly, a heamatoma is 
formed in the first hours following a fracture and inflammatory cells are released 
[69, 76]. Within the first day, mesenchymal stem cells express a number of 
BMPs which induce angiogenesis, chemotaxis, mitogenesis, cell differentiation, 
and proliferation. From day two to five, hard callus formation originates in the 
subperiosteal area. Promoted by micromotion, intramembranous ossification 
occurs. In the area between the bone ends (soft callus), early cartilage formation 
starts between days four and seven. Undifferentiated mesenchymal stem cells 
begin to proliferate by day three. Osteocalcin is expressed in the hard callus 
from day six to 10. In days 11 to 20, cellular proliferation decreases in the areas 
of hard callus formation. In the soft callus, the cartilage begins to calcify. From 
days 21 to 25, there is no more cellular proliferation. The structure in the hard 
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callus area turned into woven bone. In the soft callus, chondrocytes begin to 
undergo apoptosis and there is some cellular necrosis. Solid union with woven 
bone is present by around 35 days, succeeded by remodelling and formation of 
lamellar bone [61]. 
2.1.5 Biochemical markers 
Bone metabolism can be monitored by using special biochemical markers. The 
cellular and molecular process of signals triggering bone regeneration events is 
becoming more and more understood in vitro, but the in vivo response is still to 
a certain extent unclear. Early bone reaction to an implant is not yet understood 
completely although primary stability and long-term performance are thought to 
be related [50]. Biological processes leading to integration of an implant in bone 
mainly take place at the tissue-implant interface [77]. However, the cellular and 
molecular events that occur during normal bone healing processes can be 
influenced by the presence of a biomaterial. Bone healing processes under 
different conditions have been widely described in literature and may result in 
different bone formation. Also, molecular and cellular signalling of bone healing 
scenarios can be different. Multiple factors influence and control the complex 
interactions during bone healing. Special precursors and molecules of cytokines, 
chemokines, integrins and growth factors are temporarily recruited into the 
circulation [78]. These biochemical markers change rapidly in response to 
changes in bone formation and resorption and can be monitored by different 
techniques such as immunohistochemistry, enzyme-linked immunosorbent 
assay, western blot, microarray analysis, in situ hybridisation, and semi-
quantitative polymerase-chain reaction [79-84].  
Proinflammatory cytokines can indicate processes during the bone healing 
cascade [85]. Further biochemical markers are usually classified into those 
accociated with bone formation and resorption [86, 87]. Osteogenic cells start to 
express specific substances during their differentiation within the bone healing 
Theoretical background 
15 
cascade. Early signals of fracture healing in an early stage of bone repair 
comparing non-fractured with post-fractured rat bones have been identified [88]. 
Specific markers can indicate changes in bone processes and can exemplarily be 
used in the monitoring of anti-osteoporotic therapy [89, 90]. The analytic and 
biologic variability of bone markers can be significant and needs to be 
considered when they are used [91]. In the present thesis, quantitative PCR 
together with histological tools were used to explore the bone-implant interface. 
2.1.5.1 Proinflammatory cytokines 
The major proinflammatory cytokines are tumor-necrosis factor-alpha (TNF-α) 
and interleukin-1 beta (IL-1β). They are secreted by hematopoietic immune cells 
such as macrophages and neutrophils and have a wide range of effects [92]. 
Locksley et al. described the widespread effects of TNF member (RANKL) and 
TNF receptor superfamiliy (OPG) on signalling pathways for cell proliferation, 
survival, and differentiation and their use in the treatment for many human 
diseases [93]. Furthermore, the direct effects of TNF-α and IL-1β on 
osteoclastogenic differentiation have been largely investigated [94]. IL-1β is 
responsible for various biological activities involved in the immune and 
inflammatory response [95]. Generally, proinflammatory cytokines modulate 
inflammatory response and have a beneficial effect on regulating bone fracture 
repair [96]. TNF-α and IL-1β inhibit the expression of genes for cartilage 
extracellular matrix and potential functions in injury-induced inflammatory 
response [96]. The expression of proinflammatory cytokines increases during 
the initial inflammatory phase after bone injury within the first 24 hours [85]. 
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2.1.5.2 Bone resorption markers 
During bone resorption processes, an acidic environment is created by 
osteoclasts [31]. The released bone resorption markers can be divided into 
collagenous and non-collagenous molecules. Non-collagenous markers include 
the enzymes tartrate-resistant acid phosphatase (TRAP) and cathepsin K 
(CATK) [54]. TRAPs are metalloenzymes that catalyse the hydrolysis of various 
phosphate esters under acidic conditions. Six isoforms are identified in human 
tissue. Isoform 5 is expressed in osteoclasts and macrophages [97]. Isoform 5b 
can be used as a marker of bone resorption and indicates the number of active 
osteoclasts [98]. In bone, TRAP is found in osteoclasts and in mononuclear cells 
(osteoclast precursor cells) [99]. Not only in osteoclasts, but also in osteoblasts 
and osteocytes TRAP is expressed, but the level is much lower [100]. CATK is a 
member of cysteine protease family and is localized in vacuoles at the ruffled 
border membrane of osteoclasts [101]. This enzyme has the unique ability to 
cleave helical and telopeptide regions of collagen type I which is the major type 
of collagen in bone [102]. The degradation of collagen is a major event during 
bone resorption and CATK has an important role in osteoclastic activities [102].  
2.1.5.3 Bone formation markers 
Bone formation markers indicate osteoblastic activity [54]. Two specific and 
sensitive markers include osteocalcin (OC) and the bone specific alkaline 
phosphatase (ALP) which reflects different aspects of osteoblastic activity [103-
105]. OC is a major non-collagenous extracellular matrix protein with 46-50 
amino acids. The protein is an abundant osteoblast-specific non-collagenous 
protein and is produced during late phases of bone formation [106]. The 
structure of the protein is characterised by three γ-carboxyglutamic acid residues 
(Gla) with a high affinity to hydroxyapatite [107]. Osteocalcin is mostly 
deposited in the extracellular matrix of bone, but a small amount can also be 
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detected by immunoassay in the blood [108]. ALP is a hydrolase enzyme 
responsible for removing phosphate groups from many substances. Several ALP 
isoforms exist and some of them are bone specific. In bone, ALP is primarily 
expressed on the osteoblast cell surface. The enzyme is a potent inhibitor of 
mineralisation and important for cleaving inorganic pyrophosphates which 
promote mineral deposition in vivo [109]. Whereas OC represents a late marker 
during osteogenic differentiations for bone formation, ALP is considered an 
early differentiation marker [110]. OC and ALP gene expressions are already 
used in rat studies to indicate bone formation processes [35, 111].  
2.2 Calcium phosphates 
Calcium phosphate-like bone substitute materials have a long history of 
successful orthopaedic applications such as bone void filling and augmentation 
[7]. Many patients are treated with a bone substitute material to repair a bone 
defect resulting from an injury or a disease. Bone substitute materials based on 
calcium phosphates are of particular interest for these clinical applications.  
They have been demonstrated to be effective in a number of bone healing 
applications. Bone substitutes are proven to have an excellent in vivo 
biocompatibility and bone repair properties for example stimulating tissue 
regeneration [8-12]. Biomaterials play an important role in reconstructive 
orthopaedic surgery and it is necessary to understand the biological effects of 
these materials for their optimal application [112].  
Bioceramic materials most commonly in recent times have been based on 
hydroxyapatite and beta-tricalcium phosphate and these offer a similar structure 
to the human mineral bone phase. The large range of calcium phosphate 
formulations available can mainly be divided into three subgroups: sintered 
hydroxyapatites, solid tricalcium phosphates, and calcium phosphate cements 
[7]. Hydroxyapatite is the main inorganic component of human bones and 
widely used as the main component of an implantable medical device [113]. 
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Sintered hydroxyapatites are often used as preformed matrices with an 
interconnecting pore system to allow bone ingrowth [21]. Furthermore, the 
degradation rate of water-insoluble hydroxyapatite formulations is very slow 
[114, 115]. Solid β-tricalcium phosphates are often used as a porous 
osteoconductive bone graft substitute. An advantage of β-tricalcium phosphate is 
a reduced dissolution time when compared to sintered hydroxyapatite and 
calcium phosphate cements. A disadvantage is the limited mechanical strength. 
Commercially available β-tricalcium phosphate products are preformed 
granules, blocks, or wedges [7]. Calcium phosphate cements usually consist of 
calcium phosphate powders that are mixed with a liquid water or phosphate 
solution to obtain an injectable paste. After implantation, the compound hardens 
in situ with almost no exothermal reaction [7]. The cement is mouldable which 
ensures perfect fit at the implant site. Remodelling in bone substitutes is slow 
and incomplete, but by adding more and larger pores, like in ultraporous β-
tricalcium phosphate, complete or nearly complete resorption can be achieved 
[7]. Different surface structure and shape of commercially available biominerals 
are a result of their manufacturing process. Critical parameters are sintering 
temperature and time [116]. All these bioceramics promote the formation of new 
bone by their osteoconductive properties during the natural mineralisation 
process [8-12]. Calcium phosphates act as synthetic osteoconductive matrices 
after implantation in bone. When placed in a stable configuration adjacent to 
bone, osteoid will be formed directly on the surface of the calcium phosphate 
with no soft tissue interposed [7]. Such biomaterials are frequently used for bone 
void filling to replace bone loss [117]. A bone void filling leads subsequently to 
a bone regeneration and repair [118].  
In the clinical use of bone void fillers based on calcium phosphates, there is an 
increasing interest in an additional local pharmacological treatment to generate 
further benefits [20-23]. Many investigations have been conducted to maximize 
controlled drug release to specific bone sites to maintain a prolonged drug 
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concentration level and avoid pharmacological side effects [27]. Calcium 
phosphates are able to adsorb several chemical substances on their surfaces, 
such as proteins, antibiotics or chemotherapeutic agents [18-20]. The adsorptive 
affinity of these materials to active pharmaceuticals can be used for the 
development of innovative drug delivery systems. A potential bone substitute 
material must have the ability to incorporate pharmaceuticals at a target load and 
to deliver it to the surrounding bone tissue if it is intended to be used as a drug 
carrier. Offering an osteoconductive matrix for new bone growth and being a 
carrier for local and controlled bisphosphonate delivery, a combination product 
is very attractive for the treatment of bone diseases. Maintenance of bone 
density and reduction of bone resorption can theoretically be enhanced after 
implantation of bone substitute materials releasing bisphosphonates [28]. 
Several parameters can influence both, drug loading and release properties. A 
careful physico-chemical characterisation of bone substitute materials is, 
therefore, necessary to evaluate the feasibility of being optimal candidates for an 
innovative local drug delivery system. A short-term dipping technique for drug 
loading could be promising for a clinical application in terms of loading bone 
substitutes directly prior or during surgery with well-defined drug content. In the 
present study, a sintered body, differently sized granules, and powders were 
selected as bone substitute materials to investigate the major influencing factors. 
The choice of bone substitute materials represents three common forms of 
materials: solid, granular and an injectable paste that sets in situ. Whilst there is 
a lot of literature on drug delivery through implantable devices, there still is 
much to be learned about how to do this safely and effectively. At the time of 
writing, there is no product (combining a calcium phosphate with a 
bisphosphonate) yet available for clinical application that is approved for use in 
either Europe or United States of America. It is known that a company called 
Graftys has initiated a clinical trial in which a calcium phosphate cement is used 
to deliver a bisphosphonate [119]. 
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2.3 Osteoporosis 
The previously described bone processes do not refer to metabolic and disease-
related changes in bone structure. In addition to the above mentioned healthy 
conditions, bone structures can also be modified by bone diseases such as 
osteoporosis. Many orthopaedic patients are affected by osteoporosis resulting in 
an increased risk of bone fractures [13]. For the year 2000, nine million new 
osteoporotic fractures were estimated world-wide [14]. Osteoporosis is a 
metabolic disease affecting bone which is an important issue within the geriatric 
population primarily affecting women [120]. The disease pattern is characterized 
by a decreased bone mineral density (BMD) and microarchitectural deterioration 
of bone tissue (Figure 2.5). The mechanical strength of bone is strongly 
determined by its mass [17]. It is also shown that increased bone turnover 
correlates with an increased fracture risk [121]. This relationship has been seen 
in therapeutic trials with bisphosphonates, in which increased bone density and 
decreased bone turnover have correlated with reduced fracture risk [122]. 
Osteoporotic bone leads to a consequent increase in bone fragility and 
susceptibility to fracture [123]. Studies have shown a close correlation between 
low BMD and increased fracture risk [124, 125]. Bone architecture is not only 
affected in cancellous bone (thinning and loss of trabeculae) but also in cortical 
bone (thinning of the cortex and increase in intercortical porosity). In healthy 
bone, osteoclasts and osteoblasts constantly adjust the bone density balance. If 
the number of osteoclasts is higher than the number of osteoblasts, the bone 
density decreases. In osteoporosis, the amount of active osteoclasts and 
remodelling units are elevated and shift the balance in favour of resorption [13]. 
Furthermore, the osteoblasts are less active and fail to completely restock the 
resorption lacunae. This results in incremental porous structures of bones. With 
aging, less bone is formed by osteoblasts than removed by osteoclasts [13]. 
Estrogen deficiency increases osteoclasts’ while simultaneously decreasing 
osteoblasts’ life span. This results in an increased rate of bone remodelling 
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during the menopause which increases the risk of osteoporosis in 
postmenopausal patients [13]. The aim of medical osteoporosis treatment is to 
maintain or increase BMD and reduce exceeding bone turnover [126]. Many 
pharmacological treatments are available to affect bone loss [127]. This can be 
achieved by inhibiting bone resorption or by stimulating osteoblasts to induce 
bone formation. In first line therapy for treatment and prevention of 
osteoporosis, bisphosphonates have been shown to be one of the most effective 
inhibitors of bone resorption [17]. 
The use of conventional implants in fracture fixation of osteoporotic bone is 
limited as fixation failures are more likely to occur as a consequence of the weak 
bone structure [15, 16]. Current research that focus on implant fixation in weak 
bone structure includes optimized implant-bone interfaces such as 
hydroxyapatite coating or biodegradable welded implants [128-130]. 
Osteoporotic fractures and their adequate fixation are an important future 
challenge in traumatology. 
 
 
 
Figure 2.5: Trabecular bone architecture of normal (a) and osteoporotic 
cancellous bone (b) described by Moritz et al. [131]. 
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2.4 Bisphosphonates 
During the last decades, bisphosphonates have extensively been developed as 
drugs for the treatment and prevention of bone diseases [132]. Nowadays, there 
is preclinical evidence that bisphosphonates have antitumor activity and are 
appropriate for the treatment of metabolic bone diseases [133]. Bisphosphonates 
are drugs that influence the quality of bone in patients suffering from 
osteoporosis. The mechanisms underlying their effects are still not fully 
understood. Bisphosphonates have been used widely in the treatment of 
disorders associated with excessive bone resorption. They are effective 
inhibitors of bone resorption and one of the most effective agents available for 
the treatment and prevention of osteoporosis [134]. This property leads to their 
use in the treatment of other metabolic bone diseases in which abnormal bone 
resorption occurs such as Paget's disease of bone, fibrous dysplasia, and 
metastatic cancer of bone [135]. Bisphosphonates are stable analogues of 
inorganic pyrophosphate (P-O-P), an endogenous regulator of calcium 
metabolism preventing ectopic calcification [136]. The bridging oxygen has 
been replaced by carbon. They are compounds characterized by two C-P bonds. 
The metabolic stable P-C-P structure allows a great number of chemical 
variations. The two lateral chains on the carbon can be changed or the phosphate 
groups can be esterized [132]. Nevertheless, every bisphosphonate has its own 
chemical, physicochemical, and biological characteristics which implies that it is 
not possible to extrapolate from the results of one compound to others with 
respect to its actions [132]. Caused by a stable carbon structure, bisphosphonates 
are resistent against hydrolysis under acidic influence as decribed for 
osteoclastic enviroments. The half-life of bisphosphonates in the circulation are 
short, and they adsorp rapidly into bone because of their high affinity for 
calcium and hydroxyapatite and bind directly to mineralized bone [137]. There 
are two main generations of bisphosphonates. Non-nitrogen-containing (e.g. 
Theoretical background 
23 
etidronate (Didronel®) and clodronate (Ostac®)) and nitrogen-containing 
bisphosphonates (e.g. pamidronate (Aredia®), alendronate (Fosamax®), 
risedronate (Actonel®), ibandronate (Bondronat®) and zolendronate (Zometa®)) 
have different molecular structure modifications (Table 2.1). Russell et al. 
described their different molecular actions [138]. 
Table 2.1: Chemical structures of major bisphosphonates and their relative 
potency to inhibit bone resorption in rats modified from Fleisch 
[132]. 
Basic bisphosphonate structure 
 
Agent R1 R2 Rel. potency Brand name 
Etidonate –OH –CH3 ~ 1x Didronel® 
Clodonate –Cl –Cl ~ 10x Ostac® 
Pamidronate –OH –(CH2)2–NH2 ~ 100x Aredia® 
Alendronate –OH –(CH2)3–NH2 >100 - <1000x Fosamax® 
Risedronate –OH 
 
 
>1000 - <10000x Actonel® 
Ibandronate –OH 
 
 
>1000 - <10000x Bondronat® 
Zoledronate –OH 
 
 
>10000x Zometa® 
 
The highest potency of bisphosphonates to inhibit bone resorption in rats is 
demonstrated by ZOL which is a member of the most recent generation of 
bisphosphonates [132]. ZOL is a very potent N-containing bisphosphonate 
which may decrease the resorption of newly formed bone in rats [139]. 
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Furthermore, ZOL inhibits osteoclastic activity and regulates cell proliferation, 
differentiation, and gene expression in osteoblasts [134]. ZOL 
pharmacologically acts in the mevalonate pathway (Figure 2.6). ZOL inhibits 
the farnesyl diphosphate synthase (FPPS) which is responsible for the synthesis 
of farnesyl diphosphate (FPP) and its downstream metabolite geranylgeranyl 
diphosphate (GGP) [140]. FPP and GGP trigger the modification of small 
GTPases which are important for the regulation of osteoclasts functions [141]. 
 
 
Figure 2.6: Simplified pharmacological action of ZOL in the mevalonate 
pathway. 
The efficacy and safety of a yearly infusion of five milligram ZOL have been 
investigated in placebo-controlled, multicenter, international trials for the 
treatment of osteoporosis and the reduction of fracture risk [142, 143]. A side-
effect associated with the use of bisphosphonates is bisphosphonate-related 
osteonecrosis of the jaw, but the pathogenesis of this effect is still mostly 
unclear [144-146]. Up to date, there is no evidence of a specific association 
between osteonecrosis of the jaw and ZOL in the doses used for treatment of 
osteoporosis in postmenopausal women [147]. It has also been suggested that 
there are risks of femoral fracture, however, the risk here is considered small in 
relation to the benefit [148]. There is growing interest in using these drugs in 
combination with orthopaedic implants with the goal of improving the quality of 
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bone at the implant-bone interface and reducing the risk of implant migration 
and failure. Bisphosphonates are occasionally the most commonly used 
osteoporosis treatment, but there are other therapies that impact on bone loss. 
Current alternatives to bisphosphonates are selective estrogen receptor 
modulators (SERMs), parathyroid hormone (PTH), strontium ranelate, and 
calcitonin. Calcium and vitamin D are also associated with osteoporosis 
treatment. They are usually taken at the same time as other drugs [127]. 
Nevertheless, it is mainly bisphosphonates that have been evaluated in the role 
of combination with orthopaedic implants for the purpose of improving bony 
support or fixation. One factor that might explain this focus is the affinity for 
calcium salts and these form the basis for most bone substitutes and implant 
coatings in common use today. 
2.5 Local drug delivery 
The site of pharmacological action of a drug can mainly be divided into 
systemic and local [149]. A systemic drug therapy refers mainly to a treatment 
that affects the whole body or that acts specifically on systems that involve the 
entire body (e.g. cardiovascular, respiratory, gastrointestinal, or nervous 
systems). A local drug therapy is mainly limited to a treatment that affects a 
certain location in the body. The aim of every drug therapy is to maximize the 
therapeutic effect of the drug and minimize drug-related site effects. This can be 
mainly achieved by delivering the drug locally at the site of pharmacological 
action [150]. Not all convential systemic applications have an adequate 
biological availability. By systemic administration routes often only small drug 
amounts reach the target tissue. Furthermore, drugs could also accumulate 
locally. The general objective of local applications is to release a desired drug 
concentration level for long periods of time without reaching a toxic level [151, 
152]. Defining a locally delivered dose for beneficial biological effects 
frequently provides a lot of challenges. Nevertheless, the use of combination 
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implants as drug carriers in orthopaedic surgery could have an added value for 
bone tissue [130]. A local drug application generates many benefits as lower 
pharmacological side effects compared to systemic application due to lower 
dosages, better control of bioavailability and toxicity, and a longer duration of 
drug delivery at the site of pharmacological action [153]. Furthermore, a drug-
loaded implant provides the possibility to combine the controlled and local drug 
delivery with systemic therapy strategies. However, a careful testing of drug-
loaded implants has to be undertaken to prove the added clinical value. 
Different techniques are available to combine bisphosphonates with an implant 
[154]. The carrier systems used are mainly calcium phosphate coatings [129, 
155], polylactic-glycolic adid polymer coatings [156], and cross-linked 
fibrinogen layers which are linked to metals via silanes [157, 158]. In the 
present thesis, different calcium phosphate based drug delivery systems were 
chosen for a local application of ZOL. Calcium phosphates are proven materials 
already approved for implantation as a bone substitute whilst fibrinogen and 
polylactic-glycolic acid are well known per se but as a coating have many 
unknowns [7]. 
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3 Materials 
3.1 Zoledronic acid (ZOL) 
ZOL (1-hydroxy-2-[(1-H-imidazole-1-yl)ethylidene]1-bisphosphonate) was 
obtained from Alexis Biochemicals (Lausen, Switzerland) and used as active 
pharmaceutical agent. ZOL is a white, crystalline powder. The water used in the 
investigations was of double-distilled quality. 
3.2 Bone substitutes 
The selected bone substitute materials varied in manufacturing processes, shapes 
and compositions. These were also selected as they correspond to the main bone 
substitute implant forms available today. 
1) A LagFix® cylinder (Stryker Trauma GmbH, Schönkirchen, Germany) 
This is a hollow tube structure made up of sintered hydroxyapatite 
granules. It is designed for use in augmenting lagscrew fixation in 
fractures of the proximal femur.  
2) BoneSave® granules (Stryker Howmedica Osteonics, Limerick, Ireland)  
These are granules that contain calcium phosphate in the form of 80% 
tricalcium phosphate and 20% hydroxyapatite. They are available in two 
different sizes of 2-4 mm and 4-6 mm. These granules are indicated for 
the filling of bone voids that are non load bearing and not intrinsic to the 
stability of the bony structure.  
3) HydroSet® (Stryker Leibinger GmbH, Freiburg, Germany) 
This is an injectable self-setting calcium phosphate cement that is 
provided in a self contained surgical set containing a liquid-filled syringe 
and a powder. The liquid contains sodium hydrogen phosphate, 
polyvinylpyrrolidone (PVP) and water. The powder used in the present 
Materials 
28 
investigations contains dicalcium phosphate dihydrate and tetracalcium 
phosphate as well as trisodium citrate dihydrate. The cement is indicated 
for non load bearing bone void filling, and in the European Union is 
additionally approved for augmenting screws. 
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4 Methods 
4.1 BoneSave® sieve fractions 
To achieve BoneSave® fractions in the desired particle size range, 4-6 mm 
BoneSave® granules were ground with a mortar and a pestle followed by sieving 
on a Retsch Sieve Tower, Type Vibro (Retsch, Haan, Germany) using sieves 
500, 355, 90 and 63 PhEur. 
4.2 Physico-chemical characterisation 
A sufficient investigation of the physico-chemical characterisation of bone 
substitute materials was neccessary to assess their potential as drug carriers. 
Several parameters influence both, drug loading and release properties. 
Accordingly, the physico-chemical properties of the materials were 
characterized by using a number of investigative methods. 
4.2.1 Microscopy 
Surface structures were assessed by a digital light microscope (Keyence VHX-
500K, Keyence Deutschland GmbH, Neu-Isenburg, Germany). Visualisation of 
particle size and morphology was achieved by scanning electron microscopy 
(SEM). Scanning electron micrographs at different magnifications were taken 
using a Carl Zeiss DSM 940 scanning electron microscope (Carl Zeiss AG, 
Oberkochen, Germany). A piece of bone material was fixed on an aluminium 
stub with conductive double-sided adhesive tape (Leit-Tabs, Plano GmbH, 
Wetzlar, Germany) and sputter-coated with gold in an argon atmosphere (50 Pa) 
at 50 mA for 65 seconds (Sputter coater, Bal-Tec AG, Vaduz, Liechtenstein). 
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4.2.2 True density 
Determination of true density was performed with a helium pycnometer from 
Pycnomatic ATC (Porotec GmbH, Hofheim/Taunus, Germany). Results are 
shown in Table 5.1. All measurements were carried out in triplicate. 
4.2.3 Specific surface area 
The specific surface area of the bioceramic samples was determined with a BET 
gas adsorption method. Degassing of the samples was completed for one hour 
under vacuum at 40°C prior to analyzing the samples with a Gemini 2360 BET 
surface area analyzer (Micromeritics, Norcross, USA) using nitrogen as 
measuring gas. The BET multipoint method was used to calculate the specific 
surface area (Table 5.1). All measurements were carried out in triplicate. 
4.2.4 Particle size 
The volume based particle size distribution of HydroSet® powder was measured 
with a Sympatec HELOS laser diffractometer (Sympatec GmbH, Clausthal 
Zellerfeld, Germany) in dry powder form after dispersing with compressed air 
(2 bar). The particle size distribution is characterized by the x50 value, giving the 
percentage undersize. Values presented are the average of at least three 
determinations. 
Methods 
31 
4.2.5 Dynamic vapour sorption (DVS) 
Dynamic vapour sorption experiments were carried out with a DVS 1 (Surface 
Measurement Systems Ltd., London, UK) using a gravimetric approach to 
determine the water sorption kinetics of the different bioceramics. 
Approximately 55 mg of each bone substitute material was weighed onto a Cahn 
microbalance and dried in a dry nitrogen flow at almost 0.0% relative humidity 
(RH) until equilibrium; dry mass was used for the calculation of water uptake. 
The drying step was followed by increasing stepwise the RH in 10% increments 
until equilibrium moisture uptake was achieved up to a RH of 90%. Then, again 
the sample was stepwise dried in 10% steps to a RH of 0.0%, followed by a 
second cycle using the same protocol. 
4.2.6 pH value of aqueous bone substitute suspensions 
2 g of HydroSet® powder, BoneSave® 2-4 mm and LagFix® cylinder were added 
to 10 mL water to determine the pH value. This was done after 1, 6 and 24 hours 
with a pH 540 GLP glass electrode (Weilheim, Germany). After each 
measurement the pH value was adjusted to the initial pH value of 7.2 with nitric 
acid. The samples were shaken on a laboratory shaker (150 min-1). 
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4.3 HPLC analysis of ZOL 
The quantification of ZOL was carried out with high pressure liquid 
chromatography (HPLC) for determination of drug content and release kinetics. 
The mobile phase was a mixture of methanol (10%, v/v) and 5 mmol sodium 
hydrogen phosphate buffer (90%, v/v) that contains 6 mmol tetrabutyl-
ammonium hydrogen sulphate as ion-pair for ZOL at a pH of 2.6. A flow rate of 
0.8 mL/min and a wavelength of 208 nm were utilised for the HPLC (Waters 
Corp. Milford, MA, USA) analysis. The instrument consisted of an RP-18 
column (LiChroChart 125-4, LiChroSpher 100 RP-18, 5 µm) with a pre-column 
(LiChroChart 4-4, LiChroSpher 100 RP-18, 5 µm, both obtained from Merck, 
Darmstadt, Germany) as stationary phase, a high precision pump (Waters 600E 
Multisolvent Delivery System), an autosampler (Waters Inline Degasser AF and 
a Waters 717 plus autosampler), and a Waters UV detector (Waters 996 
Photodiode array detector). Data analysis was performed using the Waters 
Empower 1154 software. A volume of 100 µL was injected. 
In addition, three-dimensional HPLC scans were generated. As shown in Figure 
4.1, these plots provide a three-dimensional visualization of the data. The data 
was plotted on three axes; the x-axis represents time (minutes), the y-axis 
represents absorbance units (intensity), and the z-axis represents wavelength 
(nm). This enables the detection of all detectable components in the sample and 
can, for instance, be used for stability evaluations. 
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Figure 4.1: Three-dimensional HPLC plot of ZOL dissolved in water. 
4.3.1 Limit of detection (LOD) 
The LOD is the lowest concentration in a sample that can be detected, but not 
necessarily quantified, under the stated experimental conditions. The LOD is 
important for the assays of dosages containing low drug levels, especially for the 
in vitro release kinetics presented. The parameter LOD was determined on the 
basis of signal to noise ratio (3:1). Additionally, LOD was calculated by the 
method which is based on the standard deviation (SD) of the response and the 
slope (Sl) of the calibration curve using the following general equation [159]:  
LOD = 3.3 x (SD/Sl). 
The LOD was confirmed by analyzing a number of samples near this value. 
Furthermore three-dimensional scans were used for visual evaluation. Due to a 
difficult analytic and low ZOL release rates, LOD was used as the lowest level 
to quantify drug release samples in vitro. 
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4.4 ZOL load and release 
4.4.1 Drug loading procedure 
Incorporation of ZOL into the different bone substitute materials was carried out 
by dipping the biomaterials in aqueous ZOL solutions. Drug loading 
experiments were performed in a time and concentration dependent manner. The 
biomaterials were dipped for 5, 15 and 30 minutes in 5 mL of variable aqueous 
ZOL solutions (2.25x10-6, 2.25x10-5, 2.25x10-4, and 2.25x10-3 mol/L) on a 
laboratory shaker (150 min-1).  
For drug loading experiments, a LagFix® cylinder (740 mg) and for all 
BoneSave® experiments 300 mg of each material were used. The sample weight 
of HydroSet® powder was 200 mg. Furthermore, placebo plugs of the animal 
study were also used for drug loading experiments. After dipping, the materials 
were removed from the drug solution. The remaining amount of ZOL in the 
supernatant at the end of the loading procedure was determined by HPLC. The 
difference to the initial amount of ZOL present in the solution was assumed as 
the drug adsorbed onto the biomaterials. All ZOL loading experiments were 
done in triplicate to confirm reproducibility of the loading procedure. 
The samples for analysing the drug release rates were prepared as follows: for 
HydroSet®, BoneSave® 63-90 µm and BoneSave® 355-500 µm powder a special 
technique for determination of drug release kinetics was developed. 200 mg 
HydroSet®, BoneSave® 63-90 µm or BoneSave® 355-500 µm powder, 
respectively, was transferred into 5 mL of a 2.25x10-4 mol concentrated ZOL 
solution in a centrifugation tube. After two minutes shaking, the suspension was 
centrifuged for three minutes. After these five minutes the ZOL loading solution 
was removed for analysis by HPLC and the powder was dried for two hours at 
60°C. LagFix® cylinder was loaded by dipping 15 minutes in 5 mL of a  
2.25x10-4 mol aqueous ZOL solution as described previously. 350 mg 
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BoneSave® 2-4 mm granules were loaded by dipping 22 hours in 5 mL  
2.25x10-4 molar aqueous ZOL solution. 
4.4.2 In vitro drug release of ZOL 
For the drug release tests, a LagFix® cylinder (740 mg) loaded with 
77.76 ± 1.06 µg ZOL, 200 mg BoneSave® 63-90 µm fraction loaded with 
132.64 ± 2.22 µg, 200 mg BoneSave® 355-500 µm fraction loaded with 
44.12 ± 2.47 µg, 350 mg BoneSave® 2-4 mm granules loaded with 
160.28 ± 2.07 µg and 200 mg HydroSet® powder loaded with 91.04 ± 1.82 µg 
were used. Additionally, the described drug loaded placebo plugs and verum 
implants were used for evaluation of in vitro release kinetics. 
The in vitro drug release studies were performed by incubating the drug loaded 
bone substitute material in 3 mL of water at room temperature and horizontal 
shaking. The dissolution medium of drug loaded plugs was reduced to 1 mL. In 
intervals of 5, 15 and 30 minutes, the dissolution medium was collected for 
analysis and completely replaced with fresh water. The ZOL content was 
assayed by HPLC at each time point. For BoneSave® 355-500 µm, BoneSave® 
63-90 µm and HydroSet® powders 3 minutes for centrifugation of the 
suspension was included in each test occasion. All in vitro release tests were 
carried out in triplicate. 
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4.4.3 Statistical analysis 
For statistical comparison of drug load and release experiments, data of each 
material group and dipping time points were summarized (n = 9). After 
summarizing the valid data points, all relevant descriptive parameters were 
identified to assess central position and variation of the data. Normality of all 
continuous variables was assessed with the Shapiro-Wilk Test. Due to the small 
sample sizes in each group (n = 9) the prediction of a normal distribution is 
imprecise, regardless of the Shapiro-Wilk Test outcome. Therefore, the unpaired 
Mann-Whitney Test was selected for comparison. Also Monte Carlo Simulation 
was used to raise precision of test outcome. The level of significance for all tests 
was set to 95% (p < 0.05 was significant). All calculations were performed with 
the software PASW Statistics Version 18.0.2 (SPSS). 
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4.5 Stability 
Drug stability is an essential assessment to determine the quality and efficacy of 
different ZOL formulations. In order to ensure adequate drug stability, a stability 
test of ZOL under different storage conditions was performed. For the dipping 
technique used, ZOL was dissolved in water. Therefore, it was necessary to gain 
information about drug stability in an aqueous solution over a defined period of 
time when stored in different materials. The temperature dependent stability of 
ZOL stored in glass or plastic was tested. Furthermore, the stability of different 
ZOL lyophilisates was evaluated. The concentration of ZOL at various 
conditions was monitored over time by HPLC. 
4.5.1 Lyophilisation of ZOL 
The ZOL solutions were produced by first dissolving different amounts of 
mannitol (Roquette Frères, Lestrem, France), trehalose-dihydrate (Fluka AG, 
Buchs, Switzerland) or sucrose (Merck KGaA, Darmstadt, Germany) followed 
by ZOL in double distilled water under constant stirring. The solutions prepared, 
resulted in a ZOL concentration of 100 µg/mL and a carrier amount of  
5 to 20 mg/mL. Freeze-drying of the solutions was carried out using an Alpha  
1-4 laboratory-scale freeze-dryer (Christ GmbH, Osterode, Germany). 1.0 mL-
aliquots of the solutions were filled into 2R-Vials, partially stoppered and cooled 
to below minus 27°C. Then, primary drying was started for 24 hours. 
Afterwards, secondary drying at elevated temperatures took place for another 
24 hours to remove the unfrozen water. After completion of the lyophilization 
cycle, samples were stoppered under nitrogen atmosphere and then removed 
from the freeze-dryer. 
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4.5.2 ZOL stability tests 
The first test series was performed to evaluate the temperature influence to ZOL 
stability when stored in glass over a time period of 180 days. A 2.25x10-4 mol/L 
ZOL solution was prepared and samples of 1 mL were stored in HPLC glass 
vials (Waters, Milford, USA), protected from light, for defined time points, 
under four different temperature conditions (2-8°C, 25°C, 40°C and 60°C) in a 
drying chamber (Heraeus, Hanau, Germany). The 2.25x10-4 mol/L ZOL stock 
solution was measured directly after preparation and served as reference.  
For a second test series, a 2.25x10-4 mol/L ZOL solution was stored in glass or 
plastic vials for a time period of 55 days. 1 mL of ZOL solution was added to 
HPLC glass vials and HPLC plastic vials (Waters, Milford, USA). The samples 
were stored under two different temperature conditions (2-8°C and 25°C). 1 mL 
water was added to the freeze-dried sample for stability testing of different 
lyophilisate formulations. The lyophilisates were stored in glass vials at room 
temperature. At defined time points, all samples were measured by the described 
HPLC method for determination of the ZOL concentration. Additionally, three-
dimensional plots were calculated for visualisation of sample changes. Triplicate 
HPLC determinations were performed at each time point. Furthermore, visual 
examination of the samples was performed in normal laboratory light. The 
samples were examined for precipitation, colour and clarity. 
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4.6 Cytotoxicity test 
An in vitro cytotoxicity test was performed to evaluate the toxicity of ZOL. 
Such in vitro studies are helpful to screen the toxicity of new and established 
excipients used in special formulations prior to preclinical assessment in an 
animal study [160]. Cell cultures can be used as in vitro model for toxicity test 
in a living system [161].  
4.6.1 Cell line 
In the present study, a Calu-3 cell line was used for toxicity tests of ZOL 
according to the method described by Scherließ [161]. The Calu-3 (HTB-55) 
cells were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). Passage numbers 42–50 have been used for all toxicity 
tests. The cells are an adherent cell line derived from a bronchial 
adenocarcinoma (25 years old male Caucasian). The cells form a monolayer 
culture and can be cultivated in flasks, 96-well-plates and on membrane inserts 
[161]. Briefly, the cells were cultivated in minimal essential medium (MEM) 
with Earle´s salts supplemented with 10% fetal bovine serum, 1% Penicillin-
Streptomycin, 1% non-essential amino acids and 1% sodium pyruvate (all from 
Biochrom AG, Berlin, Germany) in plastic culture flasks at 37°C in an 
atmosphere of air humidified supplemented with 5% CO2. For the test, the cells 
were seeded in 96 well plates to allow numerous and simultaneous sample 
determinations. 
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4.6.2 Sample preparation 
The in vitro toxicity of ZOL was tested under three different aqueous conditions. 
Within the first test series, 1.59 mg ZOL was dissolved in 1.5 mL water. For 
preparation of eight further samples the stock solution (1060 µg/mL) was diluted 
with water resulting in 530, 265, 132.5, 66.25, 33.13, 16.56, 8.28, and 
4.14 µg/mL. For the second test, 9.93 mg ZOL was dissolved in 10 mL water. 
For preparation of eight further samples the stock solution (993 µg/mL) was 
diluted with water resulting in 496.5, 248.25, 124.13, 62.06, 31.03, 15.52, 7.76, 
and 3.88 µg/mL. After sample preparation, the osmolarity was adjusted with 
sodium chloride to a value between 290–310 mosmol. The osmolarity was 
determined with an Osmomat 030-D (Gonotec GmbH, Berlin, Germany). The 
pH values were not adjusted. In the third test series, 9.36 mg ZOL was dissolved 
in 10 mL buffer (defined mixture of water, sodium phosphate and citric acid) to 
assure a pH of 6.8 (pH 540 GLP (Weilheim, Germany)). For preparation of eight 
further samples the stock solution (936 µg/mL) was diluted with buffer resulting 
in 468, 234, 117, 58.5, 29.25, 14.63, 7.31, and 3.66 µg/mL. Afterwards, the iso-
osmolarity (290-298 mosmol) was adjusted with sodium chloride. For 
evaluating the toxicity of HydroSet® verum and placebo plugs, defined samples 
from in vitro release tests were determined. For this, two plugs of each implant 
type were incubated in 3 mL water at room temperature under horizontal 
shaking (150 min-1). After a time interval of three hours and five days the 
osmolarity of the dissolution medium was adjusted to 290–300 mosmol and 
used for in vitro cytotoxicity tests. 
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4.6.3 MTT assay 
The toxicity of ZOL was evaluated using an MTT assay described by Scherließ 
[161]. The test is based on the inhibition of mitochondrial succinate 
dehydrogenase, involving the reduction of yellow MTT under tetrazolium ring 
cleavage to a water-insoluble purple-blue formazan product. First, the medium 
was removed from the cells, 200 µL of the prepared samples were pipetted to 
each well (quadruple determination) and were incubated at 37°C for four hours. 
Afterwards, the samples were removed and 25 µL MTT solution (5 mg/mL in 
HBSS+HEPES) were added to each well and incubated for two hours. 
Subsequently, all cells were lysed with 100 µL lysis solution (5% SDS in 
DMF:water 50:50, pH 4.7) per well. A solution of 5 mM SDS (sodium dodecyl 
sulphate) in HBSS+HEPES was used as positive control (0% viability). 
Negative control (100% viability) was HBSS+HEPES. Detection and 
quantification of the formazan was performed by a multiwell plate reader 
(Thermo Spectra III Reader with software easyWINfitting, V6.0a, Tecan, 
Austria) at 570 nm (reference wavelength 690 nm). 
4.6.4 Data analysis 
For data analysis the optical density was measured accounting for the number of 
living cells. The relative cellular viability was calculated from the adsorbance 
values as a percent of the negative control. All adsorptions were converted to 
viability results individually. The mean value of four determinations was then 
taken for further calculations and analysis. 
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4.7 Characterisation of modified HydroSet® cement formulations 
For the animal study, a ZOL-loaded implant based on the HydroSet® cement had 
to be developed. A characterisation of modified HydroSet® cement formulations 
was required to evaluate the most practical loading procedure for ZOL-loaded 
implants without influencing the cement hardness. In this section, the additional 
amount of water for complete wetting of HydroSet® powder was evaluated to 
ensure homogenous drug distribution. Furthermore, the influence of different 
drug loading procedures on the cement hardness had to be determined. Finally, 
the solubility of ZOL in the HydroSet® hardening solution was tested to evaluate 
the feasibility of directly solving ZOL in the hardening solution. 
4.7.1 Semi-quantitative wetting of HydroSet® powder 
To achieve homogenous drug distribution the powder has to be fully surrounded 
by water. A wetting study was performed to find out how much additional water 
is required to completely wet HydroSet® powder. Therefore, 2 cm³ HydroSet® 
powder was placed in the standard mixing container at room temperature. The 
initial conditions were used as dry mass for the calculation of water uptake. 5% 
additional water was stepwise added to the powder with a micropipette. The 
suspension was homogenously mixed after each addition of water. The wetting 
status was macroscopically evaluated and calculated by the needed percentage 
amount of water for a fully surrounded distribution of water. These 
measurements were done in triplicate. 
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4.7.2 Characterisation of cement hardness 
Hardness measurements of different cement formulations were conducted by 
using a Zwicki Z2.5/TN1S testing machine (Zwick GmbH & Co. KG, Ulm, 
Germany). A special experimental setup for sample placement and nail 
penetration into the formulations was developed (Figure 4.2). The different 
samples were placed in the sample holder (Ø 1.7 cm). The formulation 
penetration resistance was measured by moving the nail indenter into contact 
with the bone cement formulation placed in a sample holder. The measurement 
began with a contact force of 0.04 N with a test speed of 0.2 mm/s and ended at 
a penetration of 2.5 mm into the formulation. During compression the force-
penetration profiles could be followed on a computer screen and were recorded 
by testXpert® software (version 10.0, Zwick GmbH & Co. KG, Ulm, Germany). 
The tests were performed at room temperature (21°C). Each formulation was 
measured at a time interval of 3, 6, 9, 12, 15, and 18 minutes. All time points of 
each formulation were determined in the same sample holder. Therefore, the 
sample holder had to turn 60° prior each measurement. For cement hardness 
tests four different formulations were used and prepared as follows: 
Each formulation was mixed in the regular HydroSet® mixing container and 
quantitatively transferred to the sample holder. The first sample was a mixture 
of 1.5 cm3 HydroSet® powder and 1.5 mL hardening solution. The second 
sample were prepared by mixing 1.5 cm3 HydroSet® powder, 1.5 mL hardening 
solution and 50 µL ZOL solution (3.18 mg/mL). The third formulation 
contained 1.5 cm3 HydroSet® powder, 1.5 mL hardening solution and 475 µL 
water. For the fourth sample, 1.5 cm3 HydroSet® powder was dipped in 5 mL 
water for 5 minutes. The powder was dried for 24 hours at 55°C and then mixed 
with 1.5 mL hardening solution.  
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Figure 4.2: Experimental setup for the determination of cement hardness. 
4.7.3 Solubility of ZOL in HydroSet® hardening solution 
A semi-quantitative solubility of ZOL was determined in normal HydroSet® 
hardening solution at room temperature. Defined amounts of ZOL were given to 
500 µL hardening solution. The solubility was macroscopically determined after 
30 minutes equilibration on a laboratory shaker (150 min-1). The results are 
shown in Table 5.2. 
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4.8 In vivo animal study 
A proximal tibia bone defect rat model was used for testing the short-term 
in vivo efficacy of a ZOL loaded bone cement plug. 
Male Sprague-Dawley rats were bred at the local animal care facility (EBM, 
Gothenburg University, Sweden) and housed in accordance with guidelines of 
the Animal Committee of the University of Gothenburg. The animal 
experiments were approved by the University of Gothenburg Local Ethical 
Committee for Laboratory Animals (Dnr 301/09). Surgeries, keeping and 
accommodation of the rats were carried out at EBM facility in Gothenburg 
(Sweden). A pilot study with three rats was performed, intended to verify 
surgical and post-operative procedures. Gene expression analysis was conducted 
at TATAA Biocenter AB (Gothenburg, Sweden). Histological preparation and 
analysis were performed at the Institute of Biomaterials and Cell Therapy 
(IBCT, Gothenburg, Sweden) [162]. An additional qualitative and semi-
quantitative analysis of histological slides was performed by Biomatech (Chasse 
sur Rhône, France) [163]. The animal study was supported and funded by 
Stryker Trauma GmbH (Schönkirchen, Germany). 
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4.8.1 Implants 
Moulded bone cement plugs were used for implantation (cylindrical head: 
∅ 3.5 mm, 1.3 mm depth; cylindric body: ∅ 2.4 mm, 3.0 mm depth; volume: 
14.5 mm3 (head) + 14.7 mm3 (body) = 29.2 mm3). At the bottom the plugs were 
rounded (Figure 4.3 a). 
The basic bone substitute material for the moulded plugs was HydroSet®. 
Moulding of HydroSet® plugs that were both loaded with and without ZOL was 
performed under aseptic conditions. The procedures were carried out under 
laminar airflow in a ventilated and disinfected box. Equipment to be used during 
manufacturing was either disinfected with isopropanol 70% or by heat 
sterilisation or autoclaving, depending on what was appropriate for the 
respective material. ZOL was used in a concentration intended to result in a drug 
load of 50 µg per implant (verum). HydroSet® plugs without ZOL served as 
controls (placebo). For the preparation of the ZOL solution, the drug was added 
directly to the sterile HydroSet® hardening solution, followed by sterile filtration 
(0.2 µm). The sterile hardening solution was added to HydroSet® powder 
(powder was propounded in the normal mixing container of HydroSet®). After 
mixing both compounds with the HydroSet® spatula for 30–45 seconds the 
mixture was loaded into a sterile two-piece-moulding system (Figure 4.3 b). For 
a homogeneous distribution of the still free-flowing cement mixture the cement 
was mixed with the help of a stainless steel nail. After the hardening process the 
drug loaded and non-loaded HydroSet® plugs were removed from the moulds, 
transferred into PE bags (Stericlin®) which were heat-sealed to allow transport 
without the risk of contamination (Figure 4.3 c) and labeled according to good 
preclinical practice requirements.  
Methods 
47 
  
 
Figure 4.3: Geometric shape of the HydroSet® plug (a), the corresponding 
two-piece moulding systems for manufacturing (b) and 
packaging of sterile implants (c). 
c
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4.8.2 Crushing strength of the HydroSet® bone cement plugs 
The crushing strength of the HydroSet® bone cement plugs was investigated 
using a Pharmatest PTB 300 (Pharmatest GmbH, Germany). Determination of 
crushing strength of verum and placebo plugs was performed in triplicate one 
week after plug manufacture. Wetted verum and placebo plugs were tested in 
addition. Accordingly, the plugs were stored in 1 mL water for one minute and 
tested immediately after removal. The test principle is shown in Figure 4.4. 
 
 
Figure 4.4: Principle of crushing strength test for HydroSet® bone cement 
plug. 
4.8.3 Sterility of HydroSet® bone cement plugs 
A product intended for use in an in vivo study has to pass the PhEur sterility test. 
The test was performed by membrane filtration using a Steritest II pump and a 
presterilised disposable system consisting of two filtration vessels with 
membranes, connecting tubes and needle by Millipore (Billerica, MA USA). 
The system was attached to the pump, required to filter the samples and to 
transfer the test media onto the membranes. The procedure took place under 
aseptic conditions in a laminar air flow cabin (class 2) surrounded by a 
cleanroom, standard B (determined at rest). A schematic drawing of sterility test 
principle is shown in Figure 4.5. Implant samples (4-6 plugs per test, according 
to batch size) were rinsed in a sterile bottle with 50 mL sterile sodium chloride 
peptone broth buffered, containing 0.01% polysorbate 80, by shaking for 
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5 minutes. A portion of about 10 mL of sterile saline was transferred to the 
membranes and was filtrated. Subsequently, the whole volume of the test fluid 
used for rinsing the samples was transferred to the membranes followed by 
filtration. Thereafter, the membranes were rinsed again using 100 mL of sterile 
saline. The vessels were closed at the bottom and filled with the thioglycollate 
(thio bouillon) test media and fluid soybean casein digest medium (CASO 
bouillon) (Figure 4.5). The incoming tubes were cut through and closed by 
sterile clamps. The containers with the test media were incubated for 14 days, 
thioglycollate medium at 34°C and soybean casein digest at 22.5°C. During 
incubation, the test media were visually controlled daily for any sign of turbidity 
development representing microbial growth. A sample of each batch produced 
for the animal study was tested for sterility as described above (test frequency). 
 
 
Figure 4.5: Schematic drawing of sterility test principle. 
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4.8.4 Surgical procedure 
Thirty-six male Sprague-Dawley rats (380-390 g, 10-11 weeks old) were 
divided into four experimental groups. A total of eight rats for each time point 
(one and three weeks) were designated for the PCR analysis (n = 8) and ten rats 
were designated for histological analysis. Each animal was intended to receive 
one test (verum) and one control (placebo) implant. 
Animals were fed on a standard pellet diet, received water ad libitum and were 
housed under standard conditions. For surgery, rats underwent anesthesia using 
a Univentor 400 anesthesia unit (Univentor, Zejtun, Malta) under isoflurane 
(Isoba® Vet, Schering-Plough, Uxbridge, England) inhalation (4% with an air 
flow of 650 mL/min). Anesthesia was maintained by continuous administration 
of isoflurane (2.7% with an air flow of 450 mL/min) using a mask. 
Preoperatively, analgesic treatment (Temgesic 0.03 mg/kg, Reckitt & Coleman, 
Hull, Great Britain) was administrated subcutaneously. After shaving and 
cleaning (5 mg/mL chlorhexidine in 70% ethanol), the medial aspect of the 
proximal tibial metaphysis was exposed through a 5–6 mm longitudinal skin 
incision, followed by skin and periosteum reflection with blunt instrument 
dorsally to the physis. The cortex was opened using a ∅ 2.1 mm dental drill, 
followed by performing a ∅ 2.5 mm and 3.0 mm deep drill defect, 3–6 mm from 
the proximal physis (Figure 4.6 a-c). After rinsing with saline solution, in a 
bilateral approach, one test or control implant was inserted in each tibia (Figure 
4.6 d). Implantation was blinded and randomized for placebo and verum 
implants. 
Subcutaneously, the wound was closed with resorbable polyglactin sutures (5-0, 
Vicryl, Ethicon, Johnson & Johnson, Brussels, Belgium) and, finally, the skin 
using Monocryl 4-0 (Ethicon) which is shown in Figure 4.6 e-f. Animals were 
monitored until complete recovery and afterwards returned to their cages. The 
animals recovered within a few minutes of surgery due to the controlled 
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anaesthetic dose. Each rat received analgesic treatment postoperatively 
(Temgesic 0.03 mg/kg, Reckitt & Coleman, Hull, Great Britain) twice a day for 
a period of 48 hours. 
 
   
   
Figure 4.6: Drilling procedure: 2.1 mm ∅ dental drill (cortex opening) (a), 
2.5 mm ∅ dental drill (b), bone defect (c), final implant 
position (d), wound closure (e) and after surgery (f). 
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4.8.5 Implant retrieval and processing 
The retrieval procedure was performed after one and three weeks. The rats were 
euthanized by intraperitoneal application of sodium pentobarbital (60 mg/mL; 
ATL Apoteket Production & Laboratories, Kungens Kurva, Sweden).  
For qPCR analysis, a trephine with an internal diameter of 3.6 mm was chosen 
to harvest the implant-tissue blocks. (Figure 4.7 a and c). This diameter allowed 
cutting around the outer diameter of the implant. The biopsy was immediately 
immersed in RNA Later solution (Quiagen GmbH, Hilden, Germany) and stored 
at 4°C until analysis. The sample was then homogenized, followed by RNA 
extraction and purification. Prior to qPCR analysis with the designed primers, 
the RNA was reverse transcribed to cDNA [164].  
The implant-tissue blocks for histology and histomorphometry were harvested 
en bloc by transverse sawing, and immediately transferred into formalin (Figure 
4.7 b). After dehydration in a graded series of ethanol, resin infiltration and 
embedding, ground-sections were prepared by sawing and grinding until a final 
thickness of 15-20 µm was obtained [165]. The ground-sections were stained by 
toluidine blue followed by light microscopical evaluation (Nikon Eclipse E600, 
Japan). The measurements were performed using an image software analysis 
(Easy Image Measurement 2000, Tekno Optik AB, Sweden) with x10 eyepiece 
at 10x magnification while magnification up to 40x was used for visualization 
during measurements. 
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Figure 4.7: Plug before dissection (a), medial aspect of the tibia before 
trephine drilling (b), trephine drilled sample for qPCR (c) and 
sample for histology (d). 
a b 
c d 
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4.8.6 Quantitative PCR 
Quantitative PCR was performed to determine the level of gene expression in 
cells, harvested out of the peri-implant tissue. The gene panel was composed of 
reference genes (18S RNA and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)), genes for bone formation (OC and ALP), bone resorption (TRAP 
and CATK) and inflammatory markers (TNF-α and IL1-β). Statistics were 
performed for both, normalized data and non-normalized data. The quantities of 
target genes were normalized using the expression of 18S RNA. The normalized 
relative quantities were calculated using the delta Ct method and 90% PCR 
efficiency (k*1.9∆ct) [166]. 
4.8.7 Histology 
The histological sections were prepared for qualitative evaluation and observed 
under light microscopy (Nikon Eclipse E80i, Japan) equipped with x2, x4, x10, 
x20 and x40 objectives. 
Additonal qualitative and semi-quantitative analyses of the local effects were 
performed according to the evaluation scheme, mentioned in the attachment E 
of the ISO 10993-6 standard. The parameters evaluated included cellular events 
during the inflammatory reaction (polymorphonuclear cells, lymphocytes, 
plasma cells, macrophages, giant cells/ osteoclastic cells), signs of necrosis, 
fibroplasia, fibrosis, fatty infiltrate, osteolysis, cell or tissue degeneration, as 
well as amount of fibrin, level of encapsulation and material degradation. Bone 
regeneration performance was qualitatively and semi-quantitatively assessed by 
analyzing signs of osteointegration, woven bone, osteoblastic cells, 
osteoconduction, bone density, neovessels, bone marrow signs, and bone 
remodelling. All parameters were assessed using a score with a 0-4 grading 
scale (0: absent, 1: slight, 2: moderate, 3: marked, 4: severe) as defined in 
Table 10.6 and Table 10.7. The cell type response and performance parameters 
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are selected based on ISO 10993-6 and previously published systems [167, 
168]. 
4.8.8 Histomorphometry 
Blinded histomorphometric analysis was conducted by ground-section 
technology using light optical microscopy. The parameters being assessed were 
bone-implant contact (BIC) along the implant surface perimeter and bone area 
(BA) adjacent to the implant surface as well as at a distance from the surface.  
As shown in Figure 4.8, the bone-implant contact (BIC) and bone area (BA) 
were divided into different areas (800 µm) and zones (800x250 µm) along the 
implant, representing the cortical level, endosteal level and the marrow 
compartment. For bone-implant contact (BIC), the relation of the perimeter of 
direct bone to plug contact (length of bone contacting the implant surface) and 
the entire perimeter of the implant (total length of the implant surface) was taken 
into account. For bone area (BA), the area occupied by bone was determined 
according to the areas close to the implant (0-250 µm) and at a distance (250-
500 µm) (Figure 4.8). The statistical analysis was performed for total bone-
implant contact (mean value for A, B, area 1, 2 and 3 for both proximal and 
distal side and D) and mean bone areas (mean values of area 1, 2 and 3 for both 
proximal and distal side).  
One implant of each type from a single rat of the one week group was used for 
performing x-ray analysis (data not included) and thus was not considered in the 
quantitative evaluation. Finally, the sample size was n = 9 for the one week 
group and n = 10 for the three week group. 
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Figure 4.8: Schematic drawing of histomorphometric evaluation areas. 
4.8.9 Statistical analysis 
After summarizing valid data points, all relevant descriptive parameters were 
identified to assess central position and variation of the data. Normality of all 
continuous variables was assessed with the Shapiro-Wilk Test [169]. Due to the 
small sample sizes in each group (n = 8-10) the prediction of a normal 
distribution is imprecise, regardless of the Shapiro-Wilk Test outcome. 
Therefore, the paired non-parametric Wilcoxon Rank Test and the unpaired 
Mann-Whitney Test were selected for comparison [170, 171]. Also Monte Carlo 
Simulation was used to raise precision of test outcome [172]. The level of 
significance for all tests was set to 95% (p < 0.05 was significant). All 
calculations were performed with the software PASW Statistics Version 18.0.2 
(SPSS). For comparison and to avoid biological variations, qPCR data were 
normalized. Normalization of the values to 18S was performed for each target 
gene sample. Therefore, the relative quantity value was divided by the value 
derived from 18S control sequence in the corresponding target gene. 
For graphical visualization and comparison box- and whisker plots were chosen 
for all variables (placebo and verum) and time points (one or three weeks). The 
box corresponds to the range in which the middle half (50%) of the data are 
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included (Figure 4.9). The median is shown as a line in the box. Furthermore, 
the lower quartile (25%) marks the onset of the box and the upper quartile (75%) 
the end of the box. The whiskers mark the minimum (0%) and the maximum 
data value (100%) of the data that are not outliers. Values deviating more than 
1.5 times the interquartile distance from the median were considered as outliers 
and marked as circles. Values shown in the graphs of p < 0.05 were considered 
significant and values of p < 0.01 highly significant. Statistically significant 
differences between the implant types (placebo and verum) and time points (one 
and three weeks) are labeled in the diagram by a line and the corresponding  
p-value. 
 
 
Figure 4.9: Information from a box- and whisker plot. 
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5 Results 
5.1 Physico-chemical characterisation 
5.1.1 Light microscopy/ SEM 
The visualisation of microstructures by light microscopy and SEM gave 
qualitative information about the three different bioceramic structures. The 
LagFix® cylinder, BoneSave® material and HydroSet® powder varied in 
porosity, pore structure, pore- and crystal size and pore size distribution which 
are mainly caused by the different manufacturing processes (Figure 5.1 and 
Figure 5.2). As shown in Figure 5.1, all the ceramics have non-interconnecting 
pores whilst the individual materials differ substantially with respect to the type 
of pores. LagFix® cylinder showed a few macro- and micropores without any 
interconnectivity. Only BoneSave® granules in both sizes of 2-4 mm and  
4-6 mm demonstrated a pore size range from 10 µm (Figure 5.2 b) to 300 µm 
(Figure 5.1 c). The pictures show macro- and microporosity of BoneSave® 
granules. For the smaller-sized BoneSave® fractions (Figure 5.1 d-f), the 
macroporosity is partly destroyed by the grinding process. The surface structures 
and microporosity of big and small sized BoneSave® granules are very similar 
(Figure 5.1 c-f). HydroSet® powder does not show pores and structure at all due 
to the small particle size. The SEM pictures illustrate the construction principle 
of the different materials and demonstrated how closely and homogeneously 
fused the hydroxyapatite crystals are (Figure 5.2 a-c).  
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Figure 5.1: Light microscopy of LagFix® cylinder (a), HydroSet® powder (b) 
and different sizes of granules: BoneSave® 2-4 mm (c), 
BoneSave® 63-90 µm (d), BoneSave® 90-355 µm (e) and 
BoneSave® 355-500 µm (f). 
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Figure 5.2: Scanning electron microscopy (SEM) of LagFix® cylinder (a), 
BoneSave® granules (b) and HydroSet® powder (c). 
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5.1.2 True density and specific surface area 
Another important parameter for the characterisation was the determination of 
the true density and the specific surface area (Table 5.1). The true density of the 
three different bioceramics resulted in a range of 2.65 to 3.24 g/cm3. LagFix® 
cylinder had a low surface area of less 0.1 m2/g. BoneSave® granules 
demonstrated a particle size dependent specific surface area. A low carrier 
particle size (63-90 µm) resulted in the highest specific surface area of 0.74 m2/g 
which decreases exponentially to 0.14 m2/g for BoneSave® 4-6 mm (Table 5.1). 
HydroSet® powder had a surface area of 0.45 m2/g. The light microscopic and 
SEM photographs (Figure 5.1 and Figure 5.2) confirmed that the small specific 
surface area of the bioceramics used compared to natural bone mineral is caused 
by sintering and the disappearance of micro- and macropores. 
 
Table 5.1: True density and specific surface area of different bone substitute 
materials (n = 3; errors = standard deviation). 
Bone substitute True density 
(g/cm3) 
Specific surface area 
(m2/g) 
LagFix® cylinder 3.24 ± 0.02 < 0.1 
BoneSave® 63-90 µm 
BoneSave® 90-355 µm 
BoneSave® 355-500 µm 
BoneSave® 2000-4000 µm 
BoneSave® 4000-6000 µm 
 
 
3.11 ± 0.02 
 
0.74 ± 0.07 
0.58 ± 0.01 
0.44 ± 0.01 
0.27 ± 0.01 
0.14 ± 0.03 
HydroSet® powder 
(x50 = 21.0 ± 0.4 µm) 
2.65 ± 0.01 0.45 ± 0.01 
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5.1.3 Particle size 
As shown in Figure 5.3, the particle size distribution of HydroSet® powder 
measured in compressed air exhibited an x50 of 21 ± 0.4 µm.  
 
 
Figure 5.3: Particle size distribution of HydroSet® powder. 
5.1.4 Dynamic vapour sorption (DVS) 
Water sorption kinetics was investigated by using DVS and gave information 
about the potential of a drug adsorption by dipping in an aqueous drug solution. 
LagFix® cylinder and BoneSave® granules had a low water uptake of less than 
0.03% during the whole humidity program (Figure 5.4 a and b). HydroSet® 
powder showed a water uptake up to 3% during the program. An increase in 
water uptake at 90% relative humidity was measured. The powder also showed 
higher water desorption than adsorption (Figure 5.4 c). 
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Figure 5.4: DVS kinetics of LagFix® cylinder (a), BoneSave® granules (b) 
and HydroSet® powder (c). 
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5.1.5 pH value of aqueous bone substitute suspensions 
The results of pH value determination are shown in Figure 5.5. The initial pH 
value was adjusted to 7.2 for all materials tested. HydroSet® powder resulted in 
a pH value of 8.70 ± 0.16 after one hour. After adjusting the initial pH value, 
HydroSet® powder was measured to have a pH value of 7.45 ± 0.05 after six 
hours and a pH value of 7.46 ± 0.05 after 24 hours. The highest pH value of  
9.64 ± 0.22 was measured for BoneSave® 2-4 mm after one hour. After six and 
24 hours, the pH value resulted in 9.44 ± 0.20 and 8.56 ± 0.17. LagFix® cylinder 
demonstrated the lowest pH values. A pH value of 7.49 ± 0.21 after one hour, a 
value of 7.44 ± 0.24 after six hours, and a pH value of 7.26 ± 0.19 after 24 hours 
were measured. 
 
 
Figure 5.5: pH value of bone substitute materials after different time periods 
(n = 3; error bars = standard deviation). 
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5.2 Limit of detection (LOD) 
The LOD of ZOL with the HPLC was found to be 1.3 ± 0.1 µg/mL. In order to 
visualize different drug concentrations around the calculated LOD, additionally 
three-dimensional plots are shown in Figure 5.6. The plots visualize ZOL 
detection at drug concentrations of 8.44 and 4.22 µg/mL (Figure 5.6 a and b) 
and scans near the evaluated LOD of 2.11 and 1.05 µg/mL (Figure 5.6 c and d). 
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Figure 5.6: Three-dimensional plots of different concentrated ZOL solutions: 
8.44 µg/mL (a), 4.22 µg/mL (b), 2.11 µg/mL (c), 1.05 µg/mL (d). 
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5.3 Drug load 
The objective of drug loading experiments was to evaluate the influence of drug 
concentration and the dipping time on the resulting drug adsorption. 
In Figure 5.7 the time dependent ZOL adsorption per mg of the corresponding 
bone substitute after dipping in 5 mL of a 2.25x10-4 molar ZOL solution is 
shown. The experimental setup gave information about the potential of a 
controlled short-term loading. After 5 minutes dipping a ZOL incorporation of 
0.06 µg per mg was measured for the LagFix® cylinder. The ZOL adsorption of 
the LagFix® cylinder increased in a time dependent manner. The total drug load 
after 15 minutes was found to be 0.11 µg and 0.12 µg after 30 minutes per mg 
material, respectively. The BoneSave® material demonstrated both, a time and 
particle size dependent ZOL adsorption. The BoneSave® 4-6 mm granules 
showed the lowest drug adsorption of the used BoneSave® fractions of 
0.04 µg/mg after 5 minutes and 0.05 µg/mg after 30 minutes dipping. 
BoneSave® 2-4 mm granules were loaded with 0.12 µg/mg after 5 minutes, 
increasing to 0.14 µg/mg after 15 minutes and 0.16 µg/mg after 30 minutes 
dipping. For the three sieve fractions of BoneSave® material, an increased ZOL 
incorporation for lower particle sizes was measured. BoneSave® 355-500 µm 
was loaded in a range of 0.15 to 0.24 µg ZOL per mg material during the 
30 minutes dipping experiment. A loading of 0.28 µg/mg after 5 minutes and 
0.37 µg/mg after 30 minutes dipping was measured for the BoneSave®  
90-355 µm fraction. BoneSave® 63-90 µm fraction showed the highest drug load 
of all used materials. The material was loaded with 0.57 µg after 5 minutes, 
increased to 0.59 µg after 15 minutes and 0.64 µg after 30 minutes per mg 
material. HydroSet® powder resulted in 0.45 µg/mg loading after 5 minutes, 
0.50 µg/mg after 15 minutes and 0.52 µg/mg after 30 minutes. No change in 
surface structures was detected after the dipping procedure.  
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Statistical analysis demonstrated significant differences between all material 
groups in the experimental setup presented. Selected statistically significant 
differences are shown in Figure 5.7. Under test conditions, BoneSave®  
63-90 µm demonstrated significantly higher drug loading compared to all other 
materials tested. 
 
 
Figure 5.7: Time dependent ZOL load (µg/mg) onto bone substitutes after 
dipping in 5 mL of a 2.25x10-4 molar ZOL solution (n = 3; error 
bars = standard deviation). Selected statistically significant 
differences between the material types are labeled in the diagram 
by a line and the corresponding p-value (n = 9). 
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Figure 5.8 demonstrates the time and concentration dependent ZOL adsorption 
per mg HydroSet® powder by dipping in differently concentrated ZOL solutions. 
HydroSet® powder was loaded with 1.48 µg ZOL per mg material by dipping 
5 minutes in 5 mL of a 2.25x10-3 molar concentrated ZOL solution. After 
15 minutes an increased loading of 1.69 µg per mg and after 30 minutes a 
loading of 1.86 µg/mg was determined. By dipping HydroSet® powder 
5 minutes in 5 mL 2.25x10-4 molar concentrated ZOL solution, a loading of 
0.45 µg per mg was measured. The values increased after 15 minutes 
(0.50 µg/mg) and 30 minutes (0.52 µg/mg). A controlled and reproducible drug 
load in a time and concentration dependent manner of HydroSet® powder was 
also shown to be feasible. 
 
 
Figure 5.8: Time and concentration dependent ZOL adsorption (µg/mg) to 
HydroSet® powder after dipping in 5 mL aqueous solution of 
different ZOL concentrations (n = 3; error bars = standard 
deviation). 
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Furthermore, loading efficiency (µg/mg) versus surface area (cm²) of 300 mg 
BoneSave® fractions was calculated and is shown in Figure 5.9. The calculations 
for different BoneSave® fractions allow suggestion of the dependency of the 
surface area and the amount of drug load. The total surface area (cm²) of 300 mg 
of each BoneSave® fraction was calculated with BET data (Table 5.1) and 
related to drug loading results (Figure 5.7). Generally, a higher surface area 
resulted in a higher ZOL loading. The lowest ZOL loading of 0.039–
0.048 µg/mg by dipping 5 to 30 minutes could be calculated for a BoneSave® 
surface area of 4200 cm². A surface area of 8100 cm² incorporated ZOL in a 
range of 0.118–0.161 µg/mg during dipping time. A further increase in ZOL 
loading was calculated for surface areas of 13200 and 17400 cm², resulting in 
0.146–0.244 µg/mg and 0.275–0.368 µg/mg, respectively. The highest drug load 
of 0.574–0.637 µg/mg was demonstrated for the highest surface area of 
22200 cm². 
 
 
Figure 5.9: Loading efficiency (µg/mg) versus surface area (cm²) of 300 mg 
BoneSave® fractions (n = 3; error bars = standard deviation). 
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Finally, HydroSet® placebo plugs which were used for the animal study were 
tested within drug loading experiments. Therefore, in each case three placebo 
plugs were dipped in a time and concentration dependent manner in 5 mL 
aqueous solution of different ZOL concentrations. The results of total ZOL 
adsorption (µg) to each placebo plug are shown in Figure 5.10. 
Under test conditions, a placebo plug was loaded with 12.69 ± 0.65 µg ZOL 
after dipping in 5 mL of a 2.25x10-3 molar concentrated ZOL solution for 
5 minutes. The drug load increased to 17.71 ± 0.83 µg after 15 minutes and to 
23.57 ± 1.64 µg after 30 minutes dipping. By dipping in 5 mL of a  
2.25x10-4 molar concentrated ZOL solution, the drug load was found to be in a 
range of 5.18–14.06 µg in the tested time period. Lowest drug load in a range of 
3.21–9.42 µg was measured for the lowest concentrated ZOL dipping solution 
(2.25x10-4 molar) for the different dipping time points. The weight of a single 
placebo plug was 35.08 ± 0.58 mg. In comparison to drug load per mg 
HydroSet® powder (Figure 5.8), ZOL load per mg bone cement plug was less at 
all dipping times and drug concentrations. 
 
 
Figure 5.10: Time and concentration dependent ZOL adsorption (µg) to a 
placebo plug after dipping in 5 mL aqueous solution of different 
ZOL concentrations (n = 3; error bars = standard deviation). 
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5.4 Drug release 
Besides drug adsorption, the ZOL release from the loaded bone substitutes was 
evaluated. The release profiles (ZOL release in µg per mg material) of five of 
the loaded formulations are shown in Figure 5.11. Generally the release of ZOL 
was greatest during the first 30 minutes for all materials when compared to later 
test occasions where the drug release per time rapidly decreased. The release 
rates at later test occasions in the release studies of the materials were mainly 
limited by the detection limit of ZOL. Data for release rates less than the LOD 
could not be quantified and are not shown. In addition, the levels of released 
ZOL did not correlate with the drug amount adsorbed to the different ceramics 
within the experimental time. 
The total ZOL release from LagFix® cylinder was 0.02 µg/mg during the first 
30 minutes and indicated the lowest release rates of ZOL in the materials used. 
A slightly higher release rate was observed for BoneSave® 2-4 mm granules 
which demonstrated a release of 0.04 µg/mg after 30 minutes in vitro. The total 
ZOL release of BoneSave® 355-500 mm was increased compared to BoneSave® 
2-4 mm granules and LagFix® cylinder, respectively 0.07 µg/mg versus 
0.04 µg/mg and 0.02 µg/mg. The highest drug release rate for the BoneSave® 
materials was seen for the BoneSave® 63-90 µm fraction and resulted in 
0.14 µg/mg after 30 minutes. Finally, the ZOL release from HydroSet® powder 
was 0.18 µg/mg after 30 minutes.  
Statistical analysis demonstrated significant differences between all material 
groups in the presented experimental setup. Selected statistically significant 
differences are shown in Figure 5.11. Under test conditions, HydroSet® powder 
demonstrated the highest drug release profile compared to all other tested 
materials. 
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Figure 5.11: Cumulative ZOL release (µg/mg) from HydroSet® powder, 
BoneSave® 63-90 µm, BoneSave® 355-500 µm, BoneSave® 2-
4 mm, and LagFix® cylinder (n = 3; error bars = standard 
deviation). Selected statistically significant differences between 
the release profiles of the material types are labeled in the 
diagram by a line and the corresponding p-value (n = 9). 
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In addition, the cumulative ZOL release per unit surface area (µg/cm2) was 
calculated. As shown in Figure 5.12, the ZOL release per unit surface area for 
the BoneSave® materials was less than 0.01 µg/cm2 after 5 minutes. The values 
increased to 0.01–0.02 µg/cm2 after 15 minutes and to 0.02 µg/cm2 after 
30 minutes. The values for BoneSave® 63-90 µm were higher compared to 
BoneSave® 355-500 µm and BoneSave® 2-4 mm. Furthermore, HydroSet® 
powder showed a ZOL release of 0.03 µg/cm2 after 5 minutes. After 15 and 
30 minutes HydroSet® had a cumulative drug release of 0.04 µg/cm2. 
 
 
Figure 5.12: Cumulative ZOL release per surface area (µg/cm2) from 
HydroSet® powder, BoneSave® 63-90 µm, BoneSave® 355-
500 µm, and BoneSave® 2-4 mm (n = 3; error bars = standard 
deviation). 
 
Finally, the drug release of verum plugs and drug-loaded placebo plugs was 
tested. All release rates from these plug formulations were less than the 
evaluated LOD of the described HPLC method and could not be quantified.  
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5.5 ZOL stability test 
At each sampling time, there was no evidence of precipitation. Visual 
examination of all tested vials showed them to be clear and without any change 
of colour. 
5.5.1 Temperature profile 
The results of ZOL stability in a temperature dependent manner are shown in 
Figure 5.13. A ZOL content of more than 98% up to 15 days was measured at a 
storage temperature of 2-8°C. The drug content decreased to 95.91 ± 2.0% after 
42 days. The ZOL content decreased to 88.40 ± 3.1% after 180 days storage. At 
storage temperature of 25°C, the ZOL content was 95.07 ± 2.9% after 15 days. 
At day 42, the ZOL amount was measured to be 90.57 ± 3.3%. Finally, a ZOL 
content of 81.85 ± 5.5% was determined after 180 days. At a storage condition 
of 40°C, the ZOL content was 91.43 ± 4.2% after 15 days. A decrease to 85.69 ± 
4.2% was observed at day 42. After 180 days storage at 40°C, the ZOL content 
was 72.57 ± 6.8%. At a storage temperature of 60°C, the ZOL content was 86.90 
± 4.3% after 15 days. A decrease to 65.39 ± 6.8% was measured at day 42. The 
ZOL content further decreased to 5.93 ± 5.2% after 180 days. 
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Figure 5.13: Temperature profile of ZOL stability (n = 3; error bars = 
standard deviation). 
To confirm and visualize sample changes in the data, three-dimensional scans 
were generated and evaluated. The highest degradation was seen at a storage 
temperature of 60°C. Selected three-dimensional scans showing these sample 
changes at 60°C in a time-dependent manner are presented in Figure 5.14.  
In Figure 5.14 a, the three-dimensional scan of a 2.25 x10-4 molar ZOL solution 
at day zero is shown. The peak intensity was approximately at 0.20 adsorption 
units (AU) under test conditions. After 15 days storage at 60°C, the peak 
intensity decreased to 0.14 AU (Figure 5.14 b). The peak geometry was similar 
to the peak measured at day zero. The peak intensity decreased further to 
0.12 AU at day 42 (Figure 5.14 c). Additionally, the small peak prior to the main 
ZOL peak slightly increased. After 99 days storage, the peak intensity was about 
0.055 AU (Figure 5.14 d). The convergence of both peak intensities is clearly 
seen.  
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Figure 5.14: Three-dimensional evaluation of time-dependent ZOL stability at 
a storage temperature of 60°C. 
5.5.2 Stability at different storage conditions (plastic versus glass) 
To evaluate the influence of the storage material, plastic storage containers were 
compared to glass containers. The stability results at different storage conditions 
(plastic and glass) are summarized in Figure 5.15.  
During storage in plastic, a ZOL content of more than 99% was demonstrated 
when stored for 55 days at 2-8°C and 25°C. Compared to storage in plastic, 
ZOL demonstrated less stability when stored in glass. After 19 days storage at  
2-8°C in glass, the drug content decreased to 97.74 ± 1.8%. Under the same test 
conditions, a drug concentration of 95.63 ± 2.1% was determined after 55 days 
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storage. At a storage temperature of 25°C in glass, drug assay decreased to  
95.94 ± 2.2% after 19 days and to 90.20 ± 2.6% after 55 days. 
 
Figure 5.15: ZOL stability stored in glass and plastic at different temperatures 
(n = 3; error bars = standard deviation). 
In Figure 5.16, two-dimensional HPLC scans of the same concentrated ZOL 
solution are shown when stored in different materials (plastic and glass). The 
ZOL chromatogram (when stored in plastic) showed the drug peak with a peak 
area of 5.35x106 area units (Figure 5.16 a). No other peaks are visible in this 
chromatogram. The same ZOL concentration resulted in a different 
chromatogram when stored in glass (Figure 5.16 b). In addition to the main peak 
at a retention time of about 3 minutes, another peak was discovered at a lower 
retention time. The main peak with the greater intensity had an area of 5.04x106 
area units. The small peak had an area of 2.9x105 area units. Overall, both peaks 
had a total peak area of 5.33x106 area units. This total peak area corresponded to 
almost the total peak area of the main ZOL peak when stored in plastic. 
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Figure 5.16: 2.25x10-4 mol/L concentrated ZOL solution stored in a plastic 
vial (a) and a glass vial (b) 
The differences in the chromatograms of different storage conditions were 
additionally visualized by three-dimensional HPLC plots (Figure 5.17). The 
additional peak can clearly be seen in the ZOL sample stored in glass (Figure 
5.17 b). 
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Figure 5.17: Three-dimensional plots of a 2.25x10-4 mol/L concentrated ZOL 
solution stored for one day at 40°C in plastic (a) and glass (b). 
5.5.3 Stability of lyophilisates 
A light microscopy picture of the lyophilisate structure containing 100 µg ZOL 
and 20 mg mannitol is shown in Figure 5.18. The picture demonstrates the 
lyophilisate structure after 223 days storage at room temperature. The process 
parameters selected resulted in a stable structure with mannitol as a carrier 
excipient which remained intact even after several months of storage at room 
temperature. 
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Figure 5.18: Light microscopy picture of a lyophilisate containing 20 mg 
mannitol and 100 µg ZOL. 
In Figure 5.19, a photograph of the different lyophilisate formulations is shown. 
All mannitol formulations result in a stable network (1-4). The formulations 
with trehalose (5) or sucrose (6) as carrier for ZOL resulted directly after 
manufacturing in lyophilisates that are partially or completely collapsed.  
 
 
Figure 5.19: Photograph of different lyophilisates containing 100 µg ZOL and 
5 mg (1), 10 mg (2), 15 mg (3), 20 mg (4) mannitol, 15 mg 
trehalose (5) or 15 mg sucrose (6). 
1 2 3 4 5 6 
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The stability results of different lyophilisate formulations are shown in Figure 
5.20. The data demonstrated stability with more than 98% drug content of all 
formulations during a storage period of 223 days at room temperature. 
 
Figure 5.20: Stability of different ZOL lyophilisates (n = 3; error bars = 
standard deviation). 
Furthermore, three-dimensional HPLC scans were used to demonstrate an exact 
determination of ZOL in the lyophilisate formulations with the established 
HPLC method. The different lyophilisates immediately dissolved in water. In 
Figure 5.21, the three-dimensional plots of the different mannitol lyophisates 
dissolved in water are shown. The ZOL peak appeared at a retention time of 
about 3 minutes with the same intensity in every formulation. The ZOL peak 
showed a higher intensity in every shown mannitol formulation compared to the 
mannitol peak at a lower retention time. The increasing amounts of mannitol in 
the different formulations can clearly be detected. 
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Figure 5.21: Three-dimensional plots of differently concentrated mannitol 
lyophilisate formulations with 100 µg ZOL dissolved in water: 
5 mg mannitol (a), 10 mg mannitol (b), 15 mg mannitol (c) and 
20 mg mannitol (d). 
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5.6 Cytotoxicity test 
By dissolving ZOL directly in water a Calu-3 cell viability of less than 2% could 
be evaluated within the first test series. The data are shown in Figure 5.22 and 
demonstrated low cell viability in a ZOL concentration range of  
4.14–1060 µg/mL. 
 
Figure 5.22: Cell viability (%) of different concentrated ZOL solutions 
directly dissolved in water (n = 4; error bars = standard 
deviation). 
In the second test, the osmolarity was adjusted to 290–300 mosmol. The 
resulting pH values of the prepared ZOL solutions are shown in Figure 5.23 a. 
An exponential decrease in pH was demonstrated for increasing ZOL 
concentrations. The lowest concentrated ZOL solution of 3.88 µg/mL resulted in 
a pH of 5.59 ± 0.10. For example, a pH value of 3.06 ± 0.06 was determined for 
a 993 µg/mL concentrated ZOL solution. The cell viability of the different ZOL 
solutions is shown in Figure 5.23 b. Under test conditions, the ZOL 
concentration covered a cell viability range from 99.67 ± 11.06% for the lowest 
ZOL concentration of 3.88 µg/ mL to 2.31 ± 0.47% for the highest concentrated 
ZOL solution of 993 µg/mL. Up to a concentration of 31.03 µg/mL and a pH 
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value of 4.70 ± 0.06 the cell viability was approximately 100%. The 
62.06 µg/mL concentrated ZOL solution resulted in a cell viability of 97.25 ± 
9.88%. At a concentration of 124.12 µg/ mL and a pH of 3.99 ± 0.07 the cell 
viability decreased to 76.35 ± 10.44%. A cell viability of 58.79 ± 8.50% and 
6.65 ± 5.68% respectively, was evaluated for the 248.25 µg/mL (pH of 3.66 ± 
0.12) and 496.48 µg/mL (pH of 3.34 ± 0.08) concentrated ZOL solutions. 
 
 
Figure 5.23: pH values of different iso-osmolar ZOL concentrations (a) and 
cell viability (%) of iso-osmolar ZOL solutions (b) (n = 4; error 
bars = standard deviation). 
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In the third test series, pH values and osmolarity were adjusted. The data for cell 
viability of different concentrated ZOL solutions are shown in Figure 5.24. The 
data demonstrated a cell viability of more than 85% over all tested ZOL 
concentrations in a range of 3.66–936 µg/mL. Up to a ZOL concentration of 
117 µg/ mL cell viability was higher than 95%. The cell viability slightly 
decreased to 87.14 ± 18.65% at a concentration of 234 µg/ mL and to  
86.60 ± 11.82% for the 936 µg/mL ZOL solution.  
 
Figure 5.24: Cell viability (%) of iso-osmolar ZOL solutions with an adjusted 
pH value of 6.8 (n = 4; error bars = standard deviation). 
To evaluate the toxicity of HydroSet® plugs used for the in vivo animal study, 
release samples of verum and placebo plugs were tested without adjusting the 
pH value. The data for the tested dissolution media after three hours and five 
days are shown in Figure 5.25. Both implant types and both releasing time 
points demonstrated cell viability higher than 90 %. After three hours releasing 
time, the verum plug resulted in a cell viability of 98.94 ± 19.27% and the 
placebo formulation showed 93.32 ± 15.55% cell viability. For the five days 
time point, the verum formulation had a cell viability of 90.24 ± 12.55% and the 
placebo formulation of 95.26 ± 14.95%.  
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Figure 5.25: Cell viability of release samples from HydroSet® plugs (n = 4; 
error bars = standard deviation). 
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5.7 Characterisation of modified HydroSet® formulations 
5.7.1 Semi-quantitative wetting of HydroSet® powder 
The results of semi-quantitative wetting process are shown as photographs in 
Figure 5.26. HydroSet® powder has to be mixed with at least 25% additional 
water to make sure that the powder is fully wetted (Figure 5.26 c). Even 20% 
additional water is not enough to surround the powder completely (Figure 5.26 
b). This formulation showed powder clusters. With a higher amount of 
additional water the viscosity of the suspension decreased (Figure 5.26 d). 
 
 
 
  
Figure 5.26: HydroSet® powder mixed with different amounts of water: 
pure (a), 20% (b), 25% (c), and 40% (d). 
 
a b 
c d 
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5.7.2 Cement hardness 
The influence of additional water or ZOL solution to the HydroSet® hardening 
process was evaluated by means of hardness measurements. The hardness 
measurement results are shown in Figure 5.27.  
The hardness of normal HydroSet® cement at the different time points is shown 
in Figure 5.27 a. A maximum force of 1.4 N was evaluated after 3 minutes. The 
force increased with time. After 18 minutes a maximum force of 23.47 N was 
measured. A similar profile was evaluated for the HydroSet® cement with 50 µL 
additional ZOL solution (Figure 5.27 b). The maximum force after 18 minutes 
was 26.54 N. A different profile could be measured for HydroSet® cement with 
30% additional water (Figure 5.27 c). A major effect on cement hardness was 
seen. The maximum force after 18 minutes resulted in 2.14 N. The results of 
hardness measurements of the ZOL loaded and dried HydroSet® powder are 
shown in Figure 5.27 d. This powder demonstrated a maximum force of 0.26 N 
over the whole time period. 
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Figure 5.27: Hardness measurements of normal HydroSet® cement (a), 
HydroSet® with 50 µL ZOL solution (b), HydroSet® with 30% 
additional water (c) and ZOL loaded and dried HydroSet® (d). 
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5.7.3 Solubility of ZOL in HydroSet® hardening solution 
The semi-quantitative solubility of ZOL in 500 µL HydroSet® hardening 
solution was determined to be in a range of 5.90–7.71 mg/500 µL  
(11.8–15.4 mg/mL) as calculated from the values in Table 5.2. 
 
Table 5.2:  Semi-quantitative solubility data of ZOL in HydroSet® hardening 
solution. 
total ZOL amount (mg) solubility (500 µL) 
2.64 yes 
4.16 yes 
5.90 yes 
7.71 no 
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5.8 In vivo animal study 
5.8.1 Sterility of HydroSet® bone cement plugs 
All test media and negative controls (media without sample) revealed no growth. 
The HydroSet® implants confirmed to the test for sterility according to the 
PhEur. 
5.8.2 Crushing strength 
The results of crushing strengths of dry and wet HydroSet® verum and placebo 
plugs are shown in Figure 5.28. Dry HydroSet® verum plugs had a crushing 
strength of 41.0 ± 3.6 N and dry placebo plugs demonstrated a slightly higher 
strength of 45.7 ± 2.5 N. For the wet verum plug, 20.7 ± 3.1 N was measured. 
The wet placebo implant resulted in 24.7 ± 2.5 N. 
 
 
Figure 5.28: Crushing strengths of dry and wet HydroSet® verum and placebo 
plugs (n = 3; error bars = standard deviation). 
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5.8.3 Surgeries and bone harvesting 
No inflammatory reactions (no sign of infection) and no wound healing 
disturbances were observed macroscopically at the time of sacrifice. No 
problems were seen in the animals, all survived and none showed any signs of 
illness. All implants remained in place for the one week group. After three 
weeks, all rats appeared healthy, none showed any sign of pain or infection and 
all had normal skin. One implant had the head dislocated, but the sample could 
be utilised for qPCR analysis. 
5.8.4 SEM analysis of implants 
The visualisation of moulded implant surfaces of the bone cement plugs by SEM 
presented rough structures and a porous texture with open pores and channels in 
micrometer range (Figure 5.29). 
 
  
Figure 5.29: SEM images of the plug surface in different magnifications. 
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5.8.5 Quantitative PCR analysis 
The expression of 18S ribosomal RNA subunits at the plug surface may be used 
as an indicator for the total number of cells in the bone sample adherent to the 
plug surface. The gene expression analysis in peri-implant bone surrounding the 
placebo plug showed significantly higher expression of 18S RNA both after one 
week (p < 0.001) and after three weeks (p = 0.028) compared to verum plug 
samples (Figure 4 a). A greater amount of cells were detected in placebo 
samples as indicated by higher expression of 18S RNA (Figure 5.30 a). Another 
reference gene widely used in qPCR analysis is glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Significantly decreased levels for verum plug was 
shown for the reference gene GAPDH both after one week (p = 0.003) and after 
three weeks (p = 0.021) (Figure 5.30 b). 
 
  
Figure 5.30: The 18S (a) and GAPDH (b) ribosomal RNA expression. 
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The gene expression levels at implants retrieved from verum and placebo plugs 
were compared based on the normalized data. No significant differences of 
selected genes were found between placebo and verum plugs at each time-point 
when normalized to 18S RNA (Figure 5.31). 
 
 
Figure 5.31: Gene expression in rat bone. The total (normalized) relative 
expression levels of bone formation, bone resorption and 
proinflammatory markers (log-scale). 
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5.8.6 Histological analysis 
In Figure 5.32, a light optical micrograph of a placebo bone cement plug is 
presented which shows tissue-implant interface and implant position in rat bone. 
Qualitative evaluation of histological sections revealed that all plugs were 
appropriately positioned in the tibial metaphysis.  
 
 
Figure 5.32: Light optical micrograph of an implanted placebo bone cement 
plug after one week. 
Figure 5.33 illustrates a detailed insight into the tissue-implant interface of 
placebo and verum plugs after one week and how to differentiate old and new 
bone (Figure 5.33 c). Bone tissue surrounded both implant types and was 
frequently seen in direct contact with the implant surfaces (Figure 5.33 a and b). 
No qualitative differences were found between the two types of implants. No 
adverse tissue reactions were seen in both, verum and placebo implant groups, 
providing proof for being biocompatible.  
No differences regarding bone area and bone-implant contact were observed 
after one week using qualitative comparison of histological sections of both 
implant types (Figure 5.33 a and b). 
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Figure 5.33: Light optical micrographs of a placebo (a) and a verum plug (b) 
after one week and how to differentiate old and new bone (c). 
A qualitative difference in the amount of bone area was detected by comparing 
verum and placebo plugs after three weeks (Figure 5.34). At the direct tissue-
implant interface more bone could be seen at verum plugs (Figure 5.34 a 
compared to b). 
 
 
 
Figure 5.34: Light optical micrographs of placebo (a) and verum plug (b) 
after three weeks (new bone (*)). 
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For more objective evaluation, an additional semi-quantitative histopathological 
analysis was performed [163]. The results are summarized in Table 5.3 and 
Table 5.4.  
Adjacent to placebo (one and three weeks) and verum plugs (one week), a slight 
grade of macrophages and osteoclast-like cells was observed. Close to the verum 
plugs (three weeks), no macrophages and a slight grade of healthy osteoclast-
like cells could be documented. After one week, a slight to moderate (placebo) 
and a slight grade (verum) of fibroplasia was formed around the implants. The 
signs of fibroplasia could not be identified after three weeks for both implant 
types. None of the samples showed fibrin infiltration, osteolysis or degradation. 
Around both implant types a moderate (one week) and a marked grade (three 
weeks) of osteointegration and osteoconduction with mineralized bone was 
observed. All samples indicated marked osteoblastic activity with a moderate 
level of bone density. No signs of bone remodelling were evaluated at the 
implants after one week. However, slight signs of remodelling were detected for 
both implant types after three weeks. Generally, no material degradation 
occurred. Only for placebo plugs (three weeks), a slight sign of material 
degradation could be seen.  
As a conclusion, no abnormal signs of inflammation or cytotoxicity could be 
evaluated around the plugs after one and three weeks. To a certain level, 
osteoclasts were observed in both groups and time intervals. Smaller amounts of 
macrophages were detected around the verum implant at three weeks. 
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Table 5.3: Semi-quantitative histopathological analysis of different cell 
types and their response (errors = standard deviation). 
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1w 
Placebo 0.0 ± 0.0 1.0 ± 0.0 0.0 ± 0.0 1.3 ± 0.5 0.0 ± 0.0 0.8 ± 0.4 
Verum 0.0 ± 0.0 1.0 ± 0.0 0.1 ± 0.3 1.0 ± 0.0 0.3 ± 0.5 0.9 ± 0.3 
3w 
Placebo 0.0 ± 0.0 0.8 ± 0.4 0.3 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 0.9 ± 0.3 
Verum 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 0.0 
Index: 0 = absent, 1 = slight, 2 = moderate, 3 = marked, 4 = severe 
 
Table 5.4: Semi-quantitative histopathological analysis of different 
performance parameter (errors = standard deviation). 
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1w 
Placebo 2.0 ± 0.0 2.0 ± 0.0 2.9 ± 0.3 2.0 ± 0.0 2.0 ± 0.0 3.0 ± 0.0 2.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Verum 2.0 ± 0.0 2.0 ± 0.0 3.0 ± 0.0 2.0 ± 0.0 2.0 ± 0.0 3.0 ± 0.0 2.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
3w 
Placebo 3.0 ± 0.0 0.0 ± 0.0 2.7 ± 0.5 3.0 ± 0.0 1.8 ± 0.4 3.0 ± 0.0 2.0 ± 0.0 0.7 ± 0.5 1.0 ± 0.0 
Verum 3.0 ± 0.0 0.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0 2.0 ± 0.0 3.0 ± 0.0 2.0 ± 0.0 0.1 ± 0.3 1.0 ± 0.0 
Index: 0 = absent, 1 = slight, 2 = moderate, 3 = marked, 4 = severe 
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5.8.7 Histomorphometry 
A histomorphometrical analysis was performed to gain objective data of total 
bone area (BA) and bone-implant contact (BIC) for both implant types.  
In Figure 5.35 a, the total BIC of placebo and verum plugs after one and three 
weeks implantation is shown. A total BIC of 41.18% after one week was 
evaluated for the placebo plug and 42.61% for the verum plug which indicated 
no significant differences (Figure 5.35 a). After three weeks a significant 
increase of BIC was detected for both implant types, but with a stronger 
correlation for the verum group. The BIC after three weeks resulted in 62.02% 
for the placebo plugs and 69.69% for the verum plugs. Comparing placebo and 
verum plugs after three weeks of implantation significantly increased values 
were measured for verum plugs (p = 0.029). 
In addition to total BIC, the total bone area of the two implant types and time 
points were evaluated. The data for bone area comparing areas closer (0-
250 µm) and at a distance (250-500 µm) to the plug length are shown in Table 
5.5. Comparable amounts of bone area were found close to the implant (0-
250 µm) and at a distance (250-500 µm) around both implant types after one 
week. After three weeks, more bone area was found close (0-250 µm) to both, 
verum and placebo plugs. Additionally, there was more bone area at 0-250 µm 
and 250-500 µm distances from the verum plug length in comparison to the 
placebo plug after three weeks (Table 5.5). 
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Table 5.5: Bone area (%) comparing areas closer (0-250 µm) and at a 
distance (250-500 µm) to the plug length (errors = standard 
deviation). 
 BA at 0-250 µm distance (%) BA at 250-500 µm distance (%) 
1w 
placebo 50.90 ± 6.46 51.45 ± 8.05 
verum 51.44 ± 10.16 52.93 ± 8.30 
3w 
placebo 46.26 ± 6.84 38.98 ± 10.51 
verum 72.27 ± 6.38 60.12 ± 5.61 
 
In Figure 5.35 b, the total bone area of placebo and verum plugs after one and 
three weeks implantation is shown. A total bone area of 51.18% after one week 
was evaluated for the placebo plug and 52.19% for the verum formulation which 
indicated no significant differences (Figure 5.35 b). After three weeks, the total 
bone area was significantly decreased (p = 0.019) to 42.62% for the placebo 
formulation and significantly increased (p < 0.001) to 66.19% for the verum 
group. Highly significant differences were observed for total bone area when 
comparing placebo and verum group after three weeks (p < 0.001). 
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Figure 5.35: Histomorphometric evaluation of total bone implant contact (%) 
(a) and total bone area (%) (b) out of placebo compared to 
verum plugs after one and three weeks after implantation. 
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6 Discussion 
The development of drug-loaded medical devices is challenging and based on a 
careful and comprehensive basic research. The objective of the present thesis 
was to develop calcium phosphate based drug delivery systems for local 
application of zoledronic acid (ZOL). For this kind of development many 
requirements have to be fulfilled. Firstly, the potential ability of a calcium 
phosphate to be an adequate drug carrier has to be verified. Appropriate 
analytics for ZOL detection and an adequate drug loading technique have to be 
established. Furthermore, the system has to release suitable doses of the drug 
without being cytotoxic. These must also ensure that the original intended use of 
the medical device is maintained. Finally, an in vivo animal model for the 
selected bone cement implants has to be developed and a study conducted which 
is capable of generating data for drug-loaded devices that will enable basic 
conclusions to be drawn. All the above mentioned analyses were described by a 
variety of methods and the results will now be critically reviewed. 
6.1 Physico-chemical characterisation 
The first objective of the present thesis was to evaluate the feasibility of 
different calcium phosphate based bioceramics to be drug carriers. Several 
parameters can influence both, drug loading and release properties. An adequate 
investigation and analysis of different physico-chemical properties of each bone 
substitute material was required in order to evaluate their suitability to be part of 
an innovative local drug delivery system. The choice of bone substitute 
materials represents three common forms of materials: solid, granular and an 
injectable paste that sets in situ. They were characterized by using a number of 
investigative methods such as light microscopy, scanning electron microscopy, 
true density, surface area measurement, dynamic vapour sorption, and pH value 
determination. 
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Light microscopy and SEM were seen to be adequate and practical methods to 
assess qualitative properties in the present study. The materials investigated 
varied in porosity, pore structure, pore- and crystal size which was an interesting 
basis for identifying a sufficient ZOL carrier. The true density of the different 
materials was slightly higher than that of normal human cortical bone and 
substantially higher than trabecular or osteoporotic bone density [173]. Surface 
area measurements were an indicator for the potential amount of drug adsorption 
onto the surface of the materials. A high surface area resulted in a higher drug 
adsorption onto the material surfaces. This relation might be beneficial if the use 
as a drug carrier is intended. A reduced surface area of the used materials is 
probably induced by sintering of micro- and macropores during the 
manufacturing process. All used bone substitutes offered specific surface areas 
less than 1 m2/g without an interconnective pore system. This is of the same 
order as for other hydroxyapatite ceramics [174-177]. In comparison to natural 
bone mineral the measured surface areas are much lower. Natural bone mineral 
has a specific surface area of about 87-100 m2/g [178, 179]. The specific surface 
area of synthetic, non-sintered hydroxyapatite materials are reported to be in a 
range of 17-82 m2/g [178, 179]. In addition, the specific surface area is 
important for the ingrowth of new bone. On the one hand, a small surface area is 
a disadvantage for the incorporation of drugs by adsorption; on the other hand, 
natural variability of porosity, density, surface structures and chemical 
compositions can be avoided by using sintered bone substitute materials. 
Although the specific surface area was less 1 m2/g without an interconnecting 
pore system, the results suggested enough diffusion pathways for ZOL 
adsorption and release. Small micropores could even be exploited for controlling 
drug release which is an important parameter for a use of a bone substitute as a 
drug carrier. Such ceramic materials are highly crystalline and indicate a 
substantially slower remodelling than natural bone [21, 180]. These 
characteristics might be beneficial for the development of prolonged ZOL 
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release systems. Water sorption kinetics of LagFix® cylinder and BoneSave® 
material showed low water uptake. A dipping process in an aqueous 
environment should not have any impact on material changes of both bone 
substitute materials. HydroSet® powder had a water uptake of up to 3% and a 
mass increase at 90% RH which could be caused by material changes. These 
data led to the conclusion that drug incorporation by dipping in an aqueous 
solution might have an influence to the physical and hardening properties of 
HydroSet® powder. Ionic release, leading to an alkaline milieu, can explain 
possible interaction between ZOL and the bone substitute materials. Bone 
ceramics can increase pH values [180] which was also observed for the 
materials tested. BoneSave® reacted as a base even after several neutralisations. 
This fact could influence adsorption, homogeneity of drug loading, solubility 
and stability of the drug. Sharpe et al. reported on influenced protein adsorption 
through changes of pH values [181]. Such findings are not reported for ZOL and 
could not be confirmed during the present investigations. In summary, physico-
chemical properties of the ceramics demonstrated that they are appropriate for 
use in drug delivery applications. 
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6.2 Analytics of ZOL 
An appropriate analytics for the detection of ZOL had to be established. For this 
purpose, a HPLC method was developed. An ion-pair method was adapted to an 
already published method for ZOL detection by HPLC [182]. Such an isocratic 
ion-pair HPLC method is generally suitable for ZOL detection, especially for 
stability tests [183]. ZOL contains two phospho acid groups. Their polarity is 
too strong to retain on non polar stationary phase such as RP-18 column. As a 
consequence of the poor interaction with the column, the retention time of ZOL 
was short. Therefore, an ion exchange liquid chromatographic method was 
required for the analysis [182]. The addition of tetrabutylammonium hydrogen 
sulphate as ion-pair for ZOL enhanced the hydrophobicity in the mobile phase 
and enabled the detection of ZOL. 
During in vitro release studies, HPLC measurements in later test samples were 
mainly limited by the detection limit of ZOL. Data for release rates less than the 
LOD could not be quantified and are not shown. The amount of aqueous ZOL 
solution, also when released from a calcium phosphate carrier, can be detected 
with the established HPLC method. Due to high standard deviations of very low 
concentrated drug solutions, it was not possible to quantify values less than the 
evaluated LOD which is a limitation. In comparison, other bisphosphonates with 
free amino groups (such as alendronate, palmidronate) can be labelled pre- or 
post-column with a fluorochrome to allow HPLC analysis with fluorescence 
detection being highly sensitive [184, 185]. ZOL could not easily be derivatized 
and UV absorbance was too weak for sensitive detection in column eluates. 
Sensitivity of chelate formations with aluminium-morin or iron resulted in weak 
signals. A liquid chromatography method coupled with mass spectrometry 
(LC/MS/MS) might be more sensitive, but requires a lot of effort to establish 
[186]. It was attempted to establish a LC-MS analytic for ZOL but this led to 
irreproducible data and could not be used. The analytical work on ZOL revealed 
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a number of difficulties. An alternative method for a more sensitive LOD of 
ZOL might be radioactive labelling of ZOL [187]; however, this would very 
likely induce changes in drug molecular weight and consequently might cause 
different affinity to and drug release from the bioceramics under investigation. 
Accordingly, the HPLC method established was concluded to be the method of 
choice and led to reproducible results.  
6.3 Drug load 
Another objective was to develop a straight forward approach for combining 
ZOL with bone substitute materials using short-term dipping technique. This 
approach could be promising for a clinical application in terms of loading bone 
substitutes directly prior or during surgery with a defined drug content. Another 
goal was to evaluate the materials with respect to their ZOL loading capacity in 
a time and concentration dependent manner. 
The loading procedure must ensure that an appropriate target load and drug 
release from the ceramic materials is obtained. Some studies are published 
dealing with the combination of ceramics with ZOL. Prior to discussing the 
influence of drug dipping concentrations and dipping times, it is essential to 
look at the target load and release of ZOL for an enhanced bone formation and 
reduced bone resorption in vivo. The target drug release seems to be in the low 
µg-range as ZOL is a highly potent bisphosphonate moiety [154, 155, 188-190]. 
Some investigators have shown that osteoblast proliferation is induced by ZOL 
at a concentration of 0.5x10-3 mmol and greater, and that osteoblast survival was 
significantly decreased at 0.05 mmol of ZOL [191, 192]. Seo et al. demonstrated 
that ZOL reduces unwanted bone resorption in intercalary bone allografts. The 
optimal soaking concentration for the allografts was 0.03 mmol ZOL with a 
significant increase in bone mass density [189]. Tanzer et al. reported bone 
augmentation around and within porous implants with local ZOL elution of a 
formulation with 0.05 mg ZOL [193]. Additionally, there are investigations that 
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demonstrate enhanced local bone formation for up to one year after surgery by 
direct elution of ZOL from porous implants [194]. Other studies only show such 
an effect for up to twelve weeks post-surgery [155, 193]. At the present time, 
there is no exact ZOL target release rate, or dose for an optimal effect known to 
date. Finding the most effective ZOL dosage for a bone substitute material 
would have to be performed in an in vivo dose assessment study and can not be 
evaluated in vitro. Peter et al. reported on increased mechanical implant fixation 
by local delivery of ZOL. The drug was added to a hydroxyapatite coating by 
dipping in differently concentrated ZOL solutions. The dipping concentrations 
used in this study were adapted from these investigations [155]. The present 
investigation creates a basis for the development of new drug delivery carriers, 
which can easily be loaded with relevant ZOL doses in a controlled manner by 
defined dipping technique. As demonstrated, an appropriate target ZOL load 
could be obtained after a dipping time of 5 minutes. The ZOL load of the 
materials is a function of the surface area, exemplarily shown for the BoneSave® 
material. The surface area and ZOL incorporation could be increased by milling. 
Experiments with the differently sized fractions and drug concentrations 
indicated a critical surface area for a full ZOL adsorption by dipping at defined 
conditions. An almost complete drug adsorption could be achieved by dipping 
the materials in 5 mL 2.25x10-5 and 2.25x10-6 molar ZOL solution, respectively. 
The different materials had different loading capacities for ZOL. The drug 
loading depended on the material shape, the sample weight and surface area. 
The results demonstrated the feasibility of controlled loading of the different 
shaped bone substitutes by short-term dipping. Controlled drug loading of small 
HydroSet® particles (x50= 21 ± 0.4 µm) was feasible over dipping time and 
concentration of drug solution. In conclusion, an appropriate and controlled drug 
load can be achieved by both, dipping time and drug concentration. The drug 
loading experiments demonstrated the feasibility of controlled, reproducible and 
homogeneous incorporation of ZOL into all materials. A short-term dipping 
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technique could be promising for a clinical application in terms of loading bone 
substitutes directly prior or during surgery with defined drug content as also 
suggested by Aberg et al. [188]. 
6.4 Drug release 
Another aim was to assess the bone substitutes as release systems for ZOL 
through an in vitro approach.  
In addition to assuring a target drug load, drug release rates are equally 
important and are an indicator for ZOL affinity to each material. The in vitro 
drug release kinetics of the materials were found to be similar, but differed in 
total release amounts. During release studies, the release of ZOL from the 
materials was measured for the first 30 minutes. The release rates at later test 
occasions were mainly limited by the detection limit of ZOL with the used 
HPLC. Data for release rates less than the LOD could not be quantified and are 
not shown. For later release time points very low ZOL release rates were 
concluded due to high affinity to the materials and, accordingly, not fully 
released drug from the materials. The optimal test of release rates and drug 
efficacy would require an in vivo investigation to determine beneficial biological 
effects. A major issue with in vitro drug release kinetics is the correlation to an 
in vivo environment. Conventional drug delivery methods allow the detection of 
released drug amount, but not drug location or adsorption of released drug to the 
surrounding bone tissue. The correlation of released drug amount by detection 
with conventional drug release methods to drug release in vivo is not feasible. 
To evaluate drug load and release rates from powder formulations a special 
technique was developed. A difficulty of drug release tests from powder 
formulations was the full removal of ZOL solution after the loading procedure. 
This fact could explain the high release rates for early time points. The 
BoneSave® 63-90 µm fraction demonstrated the highest ZOL load by short-term 
dipping compared to the other investigated bioceramics which demonstrated a 
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high affinity of ZOL to the BoneSave® material. Compared to the other 
BoneSave® fractions, the 63-90 µm fraction showed the highest ZOL release 
in vitro which is explained by the larger surface area and better release pathways 
for ZOL from milled material. With all other BoneSave® fractions, the release of 
ZOL in the in vitro investigations was less. The ZOL release per surface area 
showed a similar range for all used BoneSave® materials. This demonstrated that 
the affinity of ZOL to the material is based on material properties. A higher 
affinity of ZOL to BoneSave® materials compared to HydroSet® powder was 
shown by a higher ZOL release per surface area from HydroSet® powder 
compared to BoneSave® material. The low release rates of LagFix® cylinder in 
the first 30 minutes in vitro could be explained by the small surface area. The 
high drug loads and adequate release rates of HydroSet® powder suggested that 
it is feasible to develop a potent drug loaded medical device with acceptable 
ZOL release rates. However, the correlation of released drug amount in vitro to 
drug release in vivo is not feasible. Accordingly, the next step should be to gain 
in vivo confirmation of the efficacy of locally delivered ZOL from a HydroSet® 
carrier. 
The development of a drug delivery system is not limited to the use of cement. 
The in vitro findings of ZOL adsorption in relevant doses and the demonstrated 
release profile from HydroSet® powder could also be a promising basis for the 
development of an efficient pre-shaped calcium phosphate drug carrier. A study 
could be designed to prove the concept of drug delivery by applying a drug 
impregnated, moulded HydroSet® cement formulation into a cancellous bone 
defect. 
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6.5 Stability 
A further objective was to determine the stability of ZOL under different storage 
conditions and to identify a method for enhanced drug stability. 
Stability is defined by the time over which a drug retains its integrity in terms of 
quantity and chemical identity. It can be affected by environmental factors such 
as temperature, pH, humidity, light, and air [195]. Unfortunately, due to 
analytical difficulties, ZOL could not be detected in a pH-dependent stability 
experiment. One of the most important factors that can influence the degradation 
rate of drugs or stability is temperature [196]. Temperature is a factor that is 
difficult to control during transport and storage unless a controlled supply chain 
is utilised. For drug loading experiments in the present thesis, the different bone 
substitutes were dipped in an aqueous ZOL solution. Therefore, it was important 
to know how stable an aqueous ZOL solution was during storage at different 
temperatures and what influence the storage material had. Any degradation and 
hydrolysis products were detetected by evaluation of HPLC peak areas and 
three-dimensional scans. It should be noted that the presented stability study did 
not consider sterility and only evaluated chemical stability of ZOL solutions. 
Stability data demonstrated temperature dependency during storage and loss of 
ZOL activity in an aqueous solution when stored in glass vials. ZOL instability 
was detected particularly at higher temperatures. Under experimental conditions, 
ZOL seemed to react to something which could not be visualized with the three-
dimensional HPLC scans. No additional peaks could be identified in the 
corresponding scans. Due to this result, it was considered necessary to evaluate 
other opportunities to ensure adequate drug stability when loading bone 
substitutes with ZOL.  
The stability under different storage conditions demonstrated no major loss of 
ZOL in an aqueous solution when stored in a plastic vial under a range of 
different temperatures. The results indicated that ZOL seemed to be more stable 
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in plastic vials compared to glass vials. It was concluded that glass had an 
impact on ZOL stability. Bisphosphonates have chelating properties which are 
reported to be similar to those of EDTA [197]. ZOL might chelate cations out of 
glass to form complexes. According to current knowledge, no studies are 
published dealing with the storage issues accociated with ZOL. Nakamura et al. 
reported about the stability of minodronate whose structure is releated to ZOL. 
The group supported the hypothesis that minodronic acid and aluminium ions 
apparently leached from glass of ampoules build a complex that precipitates 
[198-200]. 
In case of an intraoperative loading of bone substitutes, it is important to prepare 
a ZOL solution immediately. Unfortunately, it is not possible to dissolve 
crystalline ZOL powder by adding water in an acceptable time period due to a 
very low intrinsic dissolution of ZOL. The challenge was to develop a dry ZOL 
formulation with a sufficient stability. It was necessary to look for 
pharmaceutical technologies being applicable for both, stabilizing ZOL and 
dissolving the drug immediately. A lyophilisation technique was demonstrated 
to be suitable for stabilization of ZOL. Lyophilisation is a process in which even 
thermolabile drugs can be successfully formulated almost without any loss of 
drug activity [201]. The resulting product has a very porous structure and 
excellent rehydration properties. Furthermore, the process is suitable for the 
preparation of sterile products [202]. To ensure adequate stability, most drugs 
need an additional excipient during the lyophilisation process. Conventional 
excipients are often divided into matrix former and stabilizers. A common 
matrix former substance is mannitol [203]. Sucrose and trehalose are often used 
as stabilizer substances [204, 205]. All presented formulations demonstrated 
sufficient drug stability of more than 98% during storage time of 180 days. 
However, only mannitol lyophilisates showed a stable network without 
collapsing. There may be options to use a mannitol-based lyophilisate for the 
preparation of an aqueous ZOL solution which can then be used for dipping 
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bone substitutes. The ZOL lyophilisates demonstrated promising stability and 
dissolved immediately in water. Presumably, the state of ZOL in the freeze-
dried formulations was amorphous but this was not further analysed.  
In conclusion, storage of ZOL in glass tubes could have an impact on the drug 
stability. For adequate storage stability, no glass vials or glass fibres should be 
used because of interaction between ZOL and glass. Generally, for sufficient 
stability during storage, especially for liquid formulations, attention must be 
paid to a chelate formation of ZOL with polyvalent ions. To find a suitable 
storage container for liquid ZOL formulations would be challenging. 
6.6 In vitro cytotoxicity 
Cytotoxicity tests were performed to gain information about dose-dependent 
cytotoxic effects of ZOL and if any cytotoxic effects could be expected by using 
verum and placebo implants for the in vivo study. 
The MTT assay is a useful and sensitive test for the determination of the acute 
toxicity of excipients in an in vitro system based on Calu-3 cells [161]. Cellular 
viability depends on medium conditions such as pH value and osmolarity as well 
as it is a substance characteristic. The influence of these parameters could be 
demonstrated by the present results. In the first test, ZOL was dissolved in water 
without adjusting pH and osmolarity. Non adjusted osmolarity of the samples 
would explain the toxic effect on the cells. It is known that the maximum 
viability of the Calu-3 cell line used for the present investigations, is maintained 
at a pH of 6-7 and an osmolarity of 290-390 mosmol [161]. A pH dependency 
on Calu-3 cell viability could be seen in the second test series with iso-osmolar 
ZOL solutions. ZOL reacts acidic in aqueous solutions. However, a toxic effect 
to cell viability could not be seen up to a ZOL concentration of 60 µg/mL and a 
pH value of more than 4.3. The third test series with high cell viabilities 
confirmed the expectation of a pH and osmolarity dependency of Calu-3 cells. 
Some in vitro data showed toxic effects on cells exposed to bisphosphonates 
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[206]. Zwolak et al. demonstrated that ZOL decreased the number of viable cells 
in a dose-dependent manner when released from a bone cement formulation 
[140]. They used concentrations in a range of 100 µg up to 1000 µg per 1.5 cm³ 
bone cement and concluded the inhibition of in vitro growth of cell lines from 
giant cell tumor of bone, myeloma, and renal cell carcinoma. A dose-dependent 
decrease of cell viability could not be found within the present cytotoxicity 
results for ZOL samples in which pH and osmolarity was adjusted. 
An additional major objective of the in vitro cytotoxicity test was to find out if 
the ZOL concentration of verum implants for the animal study show any toxicity 
to Calu-3 cells. The HydroSet® verum plugs used for the in vivo study, were 
loaded with 50 µg ZOL. The present investigation showed that the HydroSet® 
bone cement without ZOL as well as drug-loaded bone cement did not affect the 
number of viable Calu-3 cells. As a conclusion out of the in vitro cytotoxicity 
tests, no toxic effect for verum and placebo plugs were expected for the 
upcoming in vivo study. 
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6.7 Characterisation of modified HydroSet® formulations 
A characterisation of modified cement formulations had to be performed to 
design an applicable implant for an animal model.  
The in vitro findings of ZOL adsorption in appropriate doses and the shown 
release profile from HydroSet® powder were a promising base for the 
development of an efficient pre-shaped drug-loaded calcium phosphate bone 
cement carrier. Thus, a feasibility study was initiated intended to gain first 
in vivo experience about the efficacy of locally applied ZOL out of a HydroSet® 
carrier. The approach was to ensure the original intended use of HydoSet® 
powder as self-setting cement. 
In this part, the impact of a loading technique on cement properties had to be 
evaluated. The question of how to load HydroSet® powder without changing the 
normal setting reaction had to be answered. The presented semi-quantitative 
data out of the wetting experiments demonstrated that HydroSet® powder had to 
be mixed with at least 25% additional water in order to make sure that the 
powder was fully surrounded with water. To ensure a homogenous drug 
distribution, the powder particles had to be fully surrounded with an aqueous 
ZOL solution. The data from cement hardness measurements demonstrated that 
no hardening process occured when 30% water was added to the HydroSet® 
powder. In conclusion, it would not be possible to add HydroSet® powder to an 
aqueous ZOL solution and then mix the suspension with the HydroSet® 
hardening solution without influencing the hardness of the cement. Furthermore, 
there was also no hardening when mixing an already ZOL-loaded and dried 
HydroSet® powder with the corresponding hardening solution. Hence, it was not 
possible to have a normal hardening process when loading HydroSet® powder in 
an aqueous ZOL solution with a dipping technique. It was possible to drug load 
HydroSet® powder by adding small volumes of a highly concentrated ZOL 
solution to the mixture of powder and hardening solution without influencing 
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the normal setting reaction. Generally, the results were in line with expectations. 
Additional water retarded the hardening process which resulted in softer cement 
formulation. Even DVS data supported the conclusion that drug incorporation 
by dipping in an aqueous solution might have an influence on the physical and 
hardening properties of HydroSet® powder and on the setting reaction. However, 
an alternative ZOL loading technique for HydroSet® cement had to be 
developed. In best case, ZOL had to be added to the system without additional 
water. The solubility of ZOL in the HydroSet® hardening solution could be 
sufficient to directly dissolve ZOL in the hardening solution without influencing 
the hardening properties of HydroSet® cement. The HydroSet® hardening 
solution is highly loaded with salts and it was therefore necessary to clarify 
whether enough ZOL can be dissolved. A semi-quantitative solubility of more 
than 10 mg/mL was sufficient for the manufacturing of HydroSet® verum plugs 
for an in vivo study.  
In conclusion, the results demonstrated that no hardening process will occur 
when mixing dry HydroSet® powder (which is already loaded by dipping in an 
aqueous ZOL solution) and the HydroSet® hardening solution. A sufficient 
solubility of ZOL in the hardening solution provided an appropriate cement 
loading without a major impact on to cement setting reaction and the resulting 
hardness. For the manufacturing of ZOL-loaded HydroSet® plugs, the drug 
could be directly dissolved in the HydroSet® hardening solution. 
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6.8 In vivo animal study 
The final objective of this thesis was to test the short-term in vivo efficacy of a 
ZOL loaded bone cement plug. After establishing a sufficient implant with an 
acceptable crushing strength, HydroSet® verum and placebo plugs were 
manufactured and tested in vivo. For this purpose, a bone defect model in the 
proximal tibia of rats was used. An in vivo study was conducted to gain 
experience on how to influence bone-implant contact, bone regeneration, and 
bone area around the implant in cancellous bone. The interpretation of a drug 
loading and releasing concept using a preshaped bone cement plug was 
supported by performing quantitative polymerase chain reaction (qPCR) and 
histological analysis. 
The in vivo study illustrated an enhanced bone area and bone-implant contact for 
verum plugs after three weeks and suggested that ZOL was effectively released. 
Generally, hydroxyapatite or tricalcium phosphate coatings and bone substitute 
materials are widely used to improve the fixation of metallic implants to bone 
during the first weeks or months [20, 207, 208]. Previous investigations have 
demonstrated the feasibility of developing effective local drug delivery systems 
based on ceramic substances [22]. Several studies have shown an improved 
fixation and bone density of implants locally delivering bisphosphonates in 
bone, especially in rat bone [155, 157, 158, 193, 209-214]. Rat models have 
been used widely and can be considered a standard for testing the biological 
response of bone to implant materials in combination with bisphosphonates. In 
literature, most authors focus on describing the effect of bisphosphonates on the 
early bone formation and bone resorption in rats within the first three weeks 
[155, 157, 158, 210]. Therfore, it is appropriate to compare the present results 
with other investigations. A drawback of the rat model is the fact that the bone 
metabolism covering healing and remodelling is quite different from that 
described in humans [215]. Furthermore, the effects in osteoporotic bone 
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structures might be completely different and were not part of the present 
research. The ceramic structure of the manufactured hydroxyapatite cement 
plugs showed physico-chemical properties to be a candidate for controlled drug 
delivery purposes due to porosity, pore structure and variations in pore size, -
shape and -distribution. The exact mechanism of ZOL release from 
hydroxyapatite bone cement plug has not yet been described. Generally, the 
release of drugs from calcium phosphate based drug delivery devices depend on 
the microstructure, the drug solubility, the type of bond between drug and matrix 
and the potential degradation mechanism of the matrix [20]. The plug 
degradation was not quantified, but a substantial degradation of the 
hydroxyapatite up to three weeks could not be detected. In conclusion, the plug 
represented a non-degradable matrix during the investigated time period. Caused 
by a non-degradable hydroxyapatite matrix, a ZOL release by diffusion across a 
concentration gradient to the surrounding microenvironment through pore 
structures of the moulded bone cement plug was supposed. Within the in vivo 
study, it was not possible to comment on the released ZOL amount to the 
surrounding tissue which is a limitation. Due to a high affinity of ZOL to 
hydroxyapatite, no adequate recovery method could be developed to quantify 
remaining drug content in verum plugs after explantation. However, the 
investigations presented the described biological effects of released ZOL out of 
a bone cement plug compared to a placebo plug. 
The two main categories of bisphosphonates are non-nitrogen-containing and 
nitrogen-containing bisphosphonates [133]. Non-nitrogen-containing 
bisphosphonates are metabolized rapidly, whereas nitrogen-containing 
bisphosphonates are much more potent and are not metabolized [216]. Lin 
reported that bisphosphonates which are released from bone can be attached by 
an osteoclast, and are obviously not destroyed inside the osteoclast, but survive 
intact [206]. If the drug will be released intact after cell death, it might be 
beneficial to develop prolonged releasing ZOL formulations. A prolonged 
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release could ensure that a sufficient ZOL amount remains active locally at the 
required implantation site over a long and defined period of time. Dhert et al. 
demonstrated that the dominating biological process in the early postoperative 
period (three and seven days) is osteoclastic resorption of the interface bone, 
regardless of the implant type (calcium-phosphate coated or non-coated titanium 
implants). Two weeks after implantation bone along the implant surfaces had 
been resorbed [63]. The results of the present study gave information about the 
response of cortical and cancellous bone to a drug-loaded and non-loaded bone 
cement plug surface after one and three weeks postoperatively. The 
histomorphometrical evaluation was considered to be more reliable compared to 
histology and PCR analysis. The histomorphometric results demonstrated an 
early bone resorption process at our placebo group from one to three weeks 
which was indicated by a significant decrease in total bone area. Brånemark et 
al. found a decrease in the maximum torque of threaded implants compared to 
the direct postoperative situation in a study on cortical implant healing in rats 
after three weeks. This corresponds with the results of Dhert describing a 
decrease in bone-implant contact and thus confirms the presence of a critical 
postoperative period in terms of implant stability [217]. These results can be 
confirmed by the recent findings in the placebo group. After implantation, bone 
resorption may lead to a temporary reduction in bone-implant stability. 
Andersson et al. demonstrated a significantly increased mechanical implant 
fixation by immobilizing ZOL to a fibrinogen coated stainless steel implant after 
two and six weeks of implantation [209]. Such effects are also shown up to eight 
weeks postoperatively [211]. Histomorphometrical results received out of the 
verum group, demonstrated a significant increase in total bone area from one to 
three weeks, confirming the findings in the literature [129, 155, 158, 210, 211, 
218]. Wermelin et al. described a long-term increase in mechanical pull-out of 
the bisphosphonate which is probably explained by a long-lasting influence on 
the local balance between bone resorption and formation [211]. Such long-term 
Discussion 
119 
effects were not part of the presented study, but are in the scope for further 
investigations.  
The target drug release seems to be in a low µg-range as ZOL is a highly potent 
bisphosphonate moiety [154, 155, 188-190]. Main effects which are reported for 
ZOL were an induced osteoblast proliferation, a reduced bone resorption, an 
increase in bone mass density, and an enhanced local bone formation [189, 191-
194]. In conclusion, to date, there is no target ZOL release rate for an optimal 
effect known and the optimal dose is still not defined. In the present study, the 
ZOL amount used in combination with the described hydroxyapatite cement 
could be beneficial to increase bone-implant contact and bone area. Local and 
adequate ZOL release could reduce early bone resorption and increase net bone 
formation to avoid early biological failures, which are reported after 
implantation. Biologically, the early time points after implantation are critical 
for implant stability [219, 220]. The findings of significant differences in total 
bone-implant contact and total bone area after three weeks for the verum group 
supported an inhibition of early bone resorption by a ZOL loaded bone cement 
plug.  
Another topic in the present investigations was the ZOL effect at some distance 
from the plugs. Increased bone density at some distance from implants has also 
been described in the literature [157, 193]. Studies with ZOL coated implants 
showed that ZOL had a significant effect on bone remodelling for a distance of 
up to 400 µm [221]. Peter et al. reported about an increased bone density at 
200 µm distance from hydroxyapatite coated implants with adherent 
bisphosphonate [155]. The effects of hydroxyapatite coated cylindrical implants 
on pull-out force showed that the density of bone in the 20 µm nearest to the 
implant was important for enhanced mechanical fixation [155]. The results of 
the present study demonstrated significantly higher total bone area at  
0–250 µm distance from the verum plug length in comparison to the placebo 
plug after three weeks and confirmed in general, the findings in the literature 
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[155, 157, 193, 221]. 
Another important aspect was the toxicity of the released ZOL. In the literature 
it is described that ZOL may decrease the number of viable tumor cells in a 
dose-dependent manner [140]. In contrast, the results of the presented 
cytotoxicity test did not confirm a decreased number of viable cells for verum 
plugs. In the present in vivo study, a procedure for the analysis of gene 
expression of plug adherent cells in bone was used. The qPCR explored the 
differences in relative gene expression between verum and placebo plugs. 
During qPCR investigations, a significant higher level of 18S ribosomal RNA 
expression was determined in the placebo plugs after one and three weeks of 
implanation. A decreased cell number for the verum samples was indicated by 
lower 18S RNA expression. An explanation for the decreased viable cells could 
be the pharmacological action of ZOL in the mevalonate pathway which is 
involved in many key functions leading to the production of sterols such as 
cholesterol. These substances are essential for membrane formation [222, 223]. 
However, the amount of ZOL used in the present study is very low and thus, the 
risk of toxic effects on other cell types is suggested to be low which was also 
confirmed by in vitro cytotoxicity tests. Systemic effects or effects millimetres 
away from the implant are thought to be minimal. The gene used for 
normalization was 18S ribosomal RNA. GAPDH has frequently been considered 
as a constitutive reference gene and used to normalize changes in specific gene 
expression. GAPDH has shown to be up-regulated in many cancers and down-
regulated by chemotherapeutic drugs like the bisphosphonate ZOL. Valenti et al. 
showed that GAPDH is inaccurate for normalizing mRNA levels in studies 
investigating the effect of bisphosphonates on gene expression and it should be 
avoided [224]. Considering the present results for GAPDH, the applied ZOL led 
to the same conclusion and was therefore not used as a gene for normalization. 
Nevertheless, no significant differences in gene expression of bone formation, 
bone response markers and proinflammatory cytokines in the 18S RNA 
Discussion 
121 
normalized data were found. Omar et al. demonstrated that implant surface 
properties influence protein-cell morphology, cell recruitment and gene 
expression at the immediate implant surface during the first 24 hours after 
implant insertion in bone. It was concluded that material surface properties 
rapidly modulate the expression of receptors which are crucial for the 
inflammatory and regenerative processes at implant surfaces in vivo [225]. With 
respect to significant differences of histomorphometrical results for verum plugs 
after three weeks, it is concluded that the chosen time points of the presented 
study were not adequate to demonstrate differences of biochemical markers with 
qPCR analysis. To determine differences in biochemical markers it might be 
necessary to analyse during the first 24 hours.  
In conclusion, the results of the rat study suggest that locally administrated ZOL 
improves bone-implant contact and bone area in rats after three weeks. This also 
gave further insight into the short term beneficial effects of ZOL in enhancing 
bone-implant contact, bone regeneration and bone density in cancellous rat 
bone. However, the number of animals limited the statistical power of the study 
to detect possible differences between the groups. Furthermore, the dosage 
equivalence is still not known and further studies are needed to investigate the 
long-term and dose-dependent effects of locally induced ZOL on bone cement 
integration. Nevertheless, the ZOL-loaded HydroSet® bone cement formulation 
decreased the time period for resorption and provided a functional drug loading 
and release concept that resulted in enhanced bone formation. ZOL influenced 
the complex bone healing processes by reducing early bone resorption close to 
the implant surface whilst at the same time promoting bone formation. 
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7 Conclusion 
The findings of the present thesis support the use of calcium phosphate-based 
bone substitute materials as effective and functional delivery systems for ZOL. 
The physico-chemical properties allow drug loading of solid, granular and 
injectable bioceramics with zoledronic acid (ZOL) and provide a better 
understanding of ZOL and calcium phosphate interactions. ZOL is shown to be 
adsorbed onto bone substitutes in a time and concentration dependent manner 
under defined conditions. Sufficient in vitro release rates, without cytotoxicity, 
enable development of a feasible and potent drug loaded medical device. The 
short-term dipping technique may be applicable for use in certain clinical 
applications allowing intraoperative loading with ZOL of bone substitutes. For 
reliable storage stability of ZOL, no glass vials or glass fibres can be used 
because of interaction between ZOL and glass. Furthermore, the in vitro 
findings were a promising basis for the development of an efficient pre-shaped 
calcium phosphate bone cement plug. This implant demonstrated the 
effectiveness of a local ZOL delivery concept intended to increase total bone-
implant contact and bone area in vivo. Using a rat model, ZOL, presented in a 
hydroxyapatite bone cement plug significantly affected the bone regeneration 
process by reducing the effects of early bone resorption. The results, achieved in 
a tibial bone defect model, provided evidence that ZOL, locally administered 
from a calcium phosphate plug enhanced bone formation at the implantation site 
at an early stage. The results create a basis for further development of new drug 
delivery systems with controlled drug load and prolonged release. Overall, the 
bioceramics evaluated can be used as carrier systems for ZOL. However, further 
studies are needed to investigate dose-dependent and long-term effects of locally 
delivered ZOL on the in vivo performance of bone regeneration. 
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8 Abstract (summary) 
Calcium phosphate-like bone substitute materials have a long history of 
successful orthopaedic applications such as bone void filling and augmentation. 
Based on the clinical indications, these materials may be loaded with active 
agents by adsorption offering a perspective for providing innovative drug 
delivery systems. The highly effective antiporotic, nitrogen-containing, 
bisphosphonate zoledronic acid (ZOL) demonstrated a strong affinity to calcium 
phosphates. It has been shown to significantly impact anabolic and catabolic 
pathways in bone remodelling towards reduction of osteoclast activity. The 
effects of locally applied ZOL on the early bone formation are of scientific and 
therapeutic interest, but still not fully understood. The local application of ZOL 
on implants is considered to support implant stabilisation by reducing early bone 
resorption. Support of early bone formation and reduction of bone resorption can 
be expected after implantation of bioceramics releasing ZOL.  
The aim of the present thesis was to develop a feasible method for combining 
ZOL with bone substitutes by use of a dipping technique. The properties of three 
different materials (sintered body, granules and powder) were investigated to 
evaluate their potential as drug carriers for ZOL. This included the use of a 
range of physico-chemical methods such as light microscopy, scanning electron 
microscopy (SEM), true density, surface area measurement, dynamic vapour 
sorption (DVS), and pH value determination. In addition to the physico-
chemical characterisation, the bone substitutes were evaluated for their ZOL 
loading capacity (time and concentration). Also, the materials were assessed as 
release systems in an in vitro study. Furthermore, ZOL stability under different 
storage conditions, cytotoxicity of ZOL with a cell line and a characterisation of 
modified cement formulations were performed to design a suitable implant for 
an animal model. In an in vivo study, ZOL was released from a drug-loaded 
preshaped calcium phosphate bone cement plug, which was implanted into a 
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bone defect in the proximal tibia of rats. The aim was to gain experience about 
the short term effects of ZOL on bone implant contact, bone regeneration and 
bone area. In a short term investigation, one and three weeks post operationem, 
tissue reactions as well as bone regeneration capabilities at the implant site were 
investigated by means of histological and imaging analysis. Furthermore, tissue 
samples, harvested at placebo and verum plug sites were used to analyse the 
gene expression of selected bone-specific markers. Levels of osteocalcin (OC), 
alkaline phosphatase (ALP), cathepsin K (CATK), tartrate-resistant acid 
phosphatase (TRAP), interleukin-1β (IL-1β) and tumor necrosis factor-α (TNFα) 
were determined by using quantitative polymerase chain reaction (qPCR). Data 
were normalized against 18S and GAPDH ribosomal subunits. 
The results of the present thesis indicated differences between the bone 
substitute materials used and their potential use as a local drug delivery system 
in terms of physico-chemical properties, drug adsorption and release profiles. 
The in vitro investigations demonstrated a controlled ZOL load in a range of 
0.04 – 1.86 µg/mg material and a release of 0.02 – 0.18 µg/mg within 
30 minutes. The findings of the in vivo study showed that in the placebo 
interface a higher amount of cells could be detected as indicated by higher 
expression of small subunit ribosomal RNA (18S). Nevertheless, comparing the 
normalized data of the selected gene expression levels, no significant differences 
were detected. Histopathological analysis revealed no adverse tissue effects and 
provided evidence of biocompatibility for both implant types. The 
histomorphometric results showed a significantly higher bone to implant contact 
and bone area for ZOL loaded bone cement plug at three weeks after 
implantation. The study showed some significant differences in the biological 
tissue response to loaded and non-loaded bone cement plugs. In this model, ZOL 
was demonstrated to be effective in impacting the bone regeneration process 
towards reduction of early bone resorption and enhanced bone formation.  
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9 Summary (German version) 
Calciumphosphat-basierte Knochenersatzmaterialien werden seit langem 
erfolgreich in der Orthopädie zur Füllung von Knochendefekten und zum 
Knochenaufbau eingesetzt. Diese Materialien könnten, je nach klinischer 
Indikation, durch Adsorption mit Arzneistoffen beladen werden, was eine 
Perspektive für innovative arzneistofffreisetzende Systeme darstellt. Das 
hochpotente, antiporotisch wirkende, stickstoffhaltige Bisphosphonat 
Zoledronsäure (ZOL) weist eine hohe Affinität zu Calciumphosphaten auf. Der 
Arzneistoff hat bereits einen signifikanten Einfluss auf anabole und katabole 
Stoffwechselvorgänge während des Knochenumbaus hin zu einer reduzierten 
Osteoklastenaktivität gezeigt. Die Effekte von lokal applizierter ZOL auf die 
frühe Knochenneubildung sind von wissenschaftlichem und therapeutischem 
Interesse, bisher aber noch nicht vollständig verstanden. Eine gezielte, lokale 
Applikation von ZOL mit Hilfe eines Calciumphosphatträgers könnte zu einer 
verminderten Knochenresorption und einer erhöhten Knochenneubildung 
führen, wodurch ein Implantat gerade in einer frühen Heilungsphase stabilisiert 
werden könnte. 
Das Ziel der vorliegenden Dissertation war es, eine einfach durchzuführende 
Beladungstechnik von Knochenersatzmaterialien mit ZOL zu entwickeln. Die 
Eigenschaften von drei verschiedenen Knochenersatzmaterialien wurden mit 
Hilfe einer Vielzahl von physiko-chemischen Methoden wie z.B. 
Lichtmikroskopie, Rasterelektronenmikroskopie, Dichtebestimmungen, 
Oberflächenbestimmungen, dynamischer Wassersorption und pH-Wert 
Bestimmungen charakterisiert, um die Möglichkeiten eines potenziellen 
Arzneistoffträgers zu ermitteln. Neben der physiko-chemischen 
Charakterisierung wurden die ZOL Beladungskapazitäten der verschiedenen 
Materialien zeit- und konzentrationsabhängig ermittelt. Zusätzlich wurden die 
in vitro Freisetzungskinetiken der beladenen Materialien bestimmt. Des 
Weiteren wurde die ZOL Stabilität unter verschiedenen Lagerungsbedingungen, 
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die Zytotoxizität auf eine Zelllinie und die Charakterisierung von modifizierten 
Zementformulierungen experimentell getestet, um ein geeignetes Implantat für 
einen Tierversuch zu entwickeln. In einer in vivo Studie wurde ZOL aus einem 
vorgeformten, arzneistoffbeladenen Calciumphosphat-Knochenzementimplantat 
freigesetzt, welches in die proximale Rattentibia implantiert wurde. Das Ziel war 
es, Kenntnis über die kurzeitigen Effekte von ZOL in Bezug auf die 
Knochenimplantatkontaktfläche, die Knochenregeneration und die 
Knochenfläche zu erlangen. Innerhalb des Untersuchungszeitraumes von ein 
und drei Wochen nach Operation wurden sowohl Gewebereaktionen als auch 
Knochenregenerationsmöglichkeiten mit Hilfe von histologischen und 
bildgebenden Analysen untersucht. Ergänzend wurden Gewebeproben, die von 
Placebo- und Verumimplantaten entnommen wurden, einer 
Genexpressionsanalyse von ausgewählten knochenspezifischen Markern 
unterzogen. Die Konzentrationen von Osteocalcin (OC), Alkaliphosphatase 
(ALP), Kathepsin K (CATK), Tartrat-resistenter saurer Phosphatase (TRAP), 
Interleukin-1β und Tumornekrosefaktor α wurden über ein quantitatives 
Polymerasekettenreaktionsverfahren (qPCR) bestimmt. Die Daten wurden gegen 
18S und GAPDH ribosomale Untereinheiten normalisiert.  
Die Ergebnisse der physiko-chemischen Untersuchungen, der Arzneistoff-
adsorption und der Freisetzungskinetiken der vorliegenden Arbeit zeigten 
Unterschiede der verwendeten Knochenersatzmaterialien im Gebrauch als 
lokales, arzneistofffreisetzendes System. Die in vitro Untersuchungen 
präsentierten die Möglichkeit einer kontrollierten ZOL Beladung in einem 
Bereich von 0,04 – 1,86 µg/mg der jeweiligen Materialen und eine Freisetzung 
von 0,02 – 0,18 µg/mg innerhalb von 30 Minuten. Die Ergenisse der in vivo 
Studie zeigten, dass eine vermehrte Zellzahl an der Placebokontaktfläche 
ermittelt werden konnte, was aus einer höheren Expression der 18S RNA 
Untereinheit geschlussfolgert wurde. Beim Vergleich der normalisierten Daten 
der Genexpression konnten keine signifikanten Unterschiede ermittelt werden. 
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Eine histopathologische Auswertung ergab, dass keine nachteiligen 
Gewebereaktionen für beide Implantattypen nachgewiesen werden konnten, was 
die Vermutung einer guten Biokompatibilität unterstützt. Die histo-
morphometrischen Ergebnisse demonstrierten eine signifikant erhöhte Knochen-
Implantat-Kontaktfläche und Knochenfläche für die ZOL-beladenen Implantate 
nach drei Wochen. Zusammengefasst konnten mit Hilfe der durchgeführten 
Tierstudie signifikante Unterschiede in der biologischen Gewebeantwort von 
ZOL-beladenen Knochenzementimplantaten gezeigt werden. In dem 
verwendeten Modell beeinflusste ZOL den Knochenregenerationsprozess hin zu 
einer Verringerung der frühen Knochenresorption und einer erhöhten 
Knochenneubildung. 
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10 Attachments 
10.1 List of abbreviations 
Ø Diameter 
°C  Degree celsius 
µg Microgram (10-6 gram) 
µL Microliter (10-6 liter) 
ALP  Alkaline phosphatase 
ATCC American type culture collection 
AU Adsorption units 
BA Bone area 
BET Sorption isotherm equation according Brunauer, Emmet 
and Teller 
BIC Bone implant contact 
BMD  Bone mineral density 
BMP Bone morphogenetic protein 
BMU  Basic multicellular units 
CaP Calcium phosphate 
CASO Fluid soybean casein digest medium 
CATK  Cathepsin K 
cDNA Complementary deoxyribonucleic acid 
d Days 
DMF Dimethylformamide 
DVS  Dynamic vapour sorption 
EDTA Ethylenediaminetetraacetic acid 
FGF Fibroblast growth factor 
FPP  Farnesyl diphosphate 
FPPS  Farnesyl diphosphate synthase 
g Gram 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GGP  Geranylgeranyl diphosphate 
Gla Gamma-carboxyglutamic acid residue 
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GTPases  Hydrolase enzyme 
h Hours 
HBSS Hanks buffered salt solution 
HEPES  2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfon acid 
HMG-CoA  Hydroxy-methylglutaryl-coenzym A 
HPLC High pressure liquid chromatography 
IGF Insulin-like growth factor 
IL  Interleukin 
ISO International Organization for Standardization 
L Liter 
LC Liquid chromatography 
LOD Limit of detection 
LOQ Limit of quantification 
mA Milliampere (10-3 ampere) 
MEM   Minimal essential medium 
MeOH Methanol 
mg Milligram (10-3 gram) 
min Minute 
mL Milliliter (10-3 liter) 
mm Millimeter (10-3 meter) 
mmol Millimol (10-3 mol) 
MS Mass spectrometry 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazoliumbromide 
N Newton 
n Number of samples 
NaH2PO4 sodium hydrogen phosphate buffer 
ng  Nanometer (10-9 gram) 
nm Nanometer (10-9 meter) 
OC  Osteocalcin 
OPG Osteoprotegerin 
Pa Pascal 
PDGF Plateled-derived growth factor 
PE Polyethylene 
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pH  Potentia Hydrogenii 
PhEur Pharmacopoeia Europaea 
PTH  Parathyroid hormone 
PVP Polyvinylpyrrolidon 
qPCR  Quantitative polymerase chain reaction 
RANKL  Rezeptor activator of nuclear factor-kappa B ligand 
rH  Relative humidity  
RNA Ribonucleic acid 
RP Reversed phase 
S Svedberg units 
SD Standard deviation 
SDS  Sodium dodecyl sulphate 
SEM Scanning electron microscopy  
SERM  Selective estrogen receptor modulators 
Sl Slope  
TGF Transforming growth factor 
THF Tetrahydrofuran 
Thio Thioglycollate 
TNF-α  Tumor necrosis factor alpha 
TRAP  Tartrate-resistant acid phosphatise 
v/v Volume per volume 
w Week 
x50 50% quantile of particle size distribution 
ZOL Zoledronic acid 
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10.2 List of utilized substances 
Table 10.1: List of utilized substances. 
Substance Supplier 
BoneSave® granules  Stryker Howmedica Osteonics, Limerick, Ireland 
Ethicon Johnson & Johnson, Brussels, Belgium 
Hanks buffered salt solution Biochrom AG, Berlin, Germany 
HEPES-buffer Biochrom AG, Berlin, Germany 
HydroSet®  Stryker Leibinger GmbH, Freiburg, Germany 
Isoflurane  Schering-Plough, Uxbridge, England 
LagFix® cylinder  Stryker Trauma GmbH, Schönkirchen, Germany 
Mannitol Roquette Frères, Lestrem, France 
Methanol J.T. Baker, Deventer, Holland 
Polysorbate 80 Goldschmidt, Essen, Germany 
RNA Later solution  Quiagen GmbH, Hilden, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium chloride peptone broth Merck, Darmstadt, Germany 
Sodium hydrogene phosphate Merck, Darmstadt, Germany 
Sodium pentobarbital  ATL Apoteket Production & Laboratories, Kungens 
Kurva, Sweden 
Soybean-casein digest medium Merck, Darmstadt, Germany 
Sucrose Merck, Darmstadt, Germany 
Temgesic Reckitt & Coleman, Hull, Great Britain 
Tetrabutylammonium hydrogen sulfate Sigma-Aldrich Chemie GmbH, Steinheim 
Trehalose-dihydrate Fluka AG, Buchs, Switzerland 
Water (aqua. bidest.) In-house equipment (FinnAqua 75-E-4, 
FinnAqua, Finland) 
Zoledronic acid Alexis Biochemicals, Lausen, Switzerland 
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10.3 Raw data of qPCR analysis 
Table 10.2: Raw data of 18S RNA and GAPDH correlation. 
 
Verum Placebo 
1w 3w 1w 3w 
18S 
117273569.30 37015521.84 2236023093.00 139408568.40 
6693600.31 332446061.00 1764986360.00 1764326342.00 
596082645.10 88905676.33 842889824.70 667138181.90 
95350739.10 196303740.20 1226821242.00 702665356.30 
173819927.20 1057634539.00 1431081145.00 1125148723.00 
416003633.90 305775533.50 1035928209.00 575362415.10 
308048741.30 34485814.62 910376929.10 919245721.90 
350243560.20 702274856.50 471627829.80 1337805248.00 
GAPDH 
34558.40 13989.10 572580.80 97019.30 
6117.20 199120.00 313138.80 735142.90 
115541.40 22317.00 210368.70 517080.40 
24332.70 56239.60 891790.10 273990.20 
25693.50 415992.70 364035.10 406030.10 
82659.70 326403.80 297649.30 151584.90 
81068.30 21913.10 128391.90 363401.40 
251029.10 74031.60 63857.30 1059891.30 
 
 
Table 10.3: Not normalized raw data of the gene panel. 
 
Verum Placebo 
1w 3w 1w 3w 
18S 
157813228.30 58119920.99 3032660988.00 174343645.20 
20329699.88 382952887.20 2224234279.00 1821454110.00 
727610485.60 135874926.90 1056068934.00 656974764.30 
134461553.10 209959329.50 1691404720.00 630236336.40 
323295525.50 1032210436.00 1864648708.00 1104304367.00 
551758088.90 300847691.10 1412885862.00 560870885.10 
520787899.20 60362186.65 1184212691.00 1129118277.00 
537107721.40 259124153.50 661001033.50 1301223802.00 
OC 
855457.82 579739.56 9803111.05 400128.64 
51907.91 2840977.78 9772757.06 11872841.06 
3851797.10 313138.76 2654959.28 966191.97 
833310.77 823359.72 902534.60 3046615.90 
902534.60 3589814.91 5845202.66 7044542.06 
3259102.46 2202647.18 5770171.47 2827742.69 
877127.15 209603.51 2031354.72 2725239.88 
4235133.23 1154569.72 2821638.98 8295502.41 
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ALP 
10198.99 7582.42 269499.74 9045.73 
1344.78 18691.79 180630.68 186826.03 
72725.45 4355.47 42450.43 17700.81 
6185.44 9204.91 115832.31 38263.94 
27231.67 50827.08 125044.76 67894.90 
42260.65 15426.77 186188.64 37946.69 
20662.66 5724.05 66028.32 60574.32 
46687.79 14221.91 37555.07 110340.04 
TRAP 
18944.42 11807.49 977197.44 24213.69 
4996.34 82359.35 660948.95 553628.15 
229886.42 9810.53 188445.01 68174.70 
29723.89 38870.89 424653.98 142614.28 
56796.79 219972.64 511656.24 305138.65 
116901.74 35083.07 940700.48 72689.51 
82223.94 9203.58 290790.04 113389.56 
116918.59 38075.52 298251.38 397028.78 
CATK 
157105.26 78417.29 7702431.41 247248.94 
6507.06 1387035.48 4669970.40 3153433.43 
1312801.57 130179.23 1429344.30 888404.58 
215169.15 305138.65 2985002.95 1624700.63 
821037.44 2476451.39 4549215.46 3248576.24 
1091754.45 479243.17 4115598.23 550858.42 
1286859.67 44673.32 1342101.03 852089.27 
917378.32 423557.13 4695721.19 2396809.09 
TNF-α 
113.35 77.72 3817.48 132.64 
215.36 553.14 3212.36 5453.74 
1225.07 371.90 1862.63 1125.80 
132.22 260.39 1278.58 780.91 
95.93 1849.27 1781.17 4371.85 
239.64 918.65 1101.35 811.24 
219.94 56.31 1395.32 1274.43 
451.66 148.07 233.30 1493.57 
IL-1β 
7484.80 681.63 11525.89 1480.70 
188.17 7003.24 17525.36 10187.52 
9214.01 36812.30 7741.70 11015.59 
3299.46 3256.37 10396.21 12283.56 
1467.00 10583.15 7077.98 14329.09 
4294.37 8968.63 5398.82 7026.53 
2219.95 272.15 8171.73 11412.17 
2444.85 1768.13 1690.87 10236.26 
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Table 10.4: Raw data of the gene panel normalized to 18S RNA. 
 
Verum Placebo 
1w 3w 1w 3w 
OC 
0.005420698 0.010083768 0.003231812 0.002293641 
0.002566629 0.007418609 0.004413333 0.006509623 
0.005297034 0.002307459 0.002522346 0.001472122 
0.006204541 0.003991150 0.000532948 0.004850184 
0.002788257 0.003485678 0.003141338 0.006397310 
0.005907003 0.007300641 0.004084719 0.005056177 
0.001684231 0.003451587 0.001715363 0.002462069 
0.007916256 0.004533806 0.004272429 0.006329575 
ALP 
0.000064627 0.000129803 0.000088912 0.000052112 
0.000066308 0.000048630 0.000081852 0.000101978 
0.000099976 0.000031831 0.000040185 0.000027116 
0.000046077 0.000044269 0.000068463 0.000060831 
0.000083953 0.000048950 0.000067319 0.000061323 
0.000076615 0.000051294 0.000131686 0.000067607 
0.000039692 0.000094678 0.000055757 0.000055413 
0.000088018 0.000055847 0.000056832 0.000085073 
TRAP 
0.000120043 0.000202609 0.000321848 0.000138408 
0.000247544 0.000214746 0.000299603 0.000304887 
0.000315557 0.000071893 0.000180053 0.000103976 
0.000219985 0.000185135 0.000251193 0.000226882 
0.000175927 0.000213253 0.000273490 0.000276830 
0.000211854 0.000116626 0.000664743 0.000129733 
0.000157806 0.000154281 0.000245556 0.000100007 
0.000219408 0.000146939 0.000443146 0.000306063 
CATK 
0.000995514 0.001349690 0.002539826 0.001419776 
0.000324597 0.003646029 0.002120276 0.001727190 
0.001817572 0.000957490 0.001345175 0.001356281 
0.001599964 0.001473321 0.001769756 0.002581986 
0.002564441 0.002394028 0.002421206 0.002946833 
0.001978031 0.001597294 0.002905622 0.000982330 
0.002473122 0.000750765 0.001133328 0.000774644 
0.001724940 0.001643372 0.007240932 0.001838278 
TNF-α 
0.000000718 0.000001307 0.000001260 0.000000756 
0.000010760 0.000001432 0.000001457 0.000002998 
0.000001665 0.000002749 0.000001808 0.000001714 
0.000000980 0.000001299 0.000000756 0.000001233 
0.000000298 0.000001794 0.000000960 0.000003969 
0.000000440 0.000003054 0.000000779 0.000001451 
0.000000423 0.000000942 0.000001178 0.000001174 
0.000000856 0.000000556 0.000000366 0.000001145 
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IL-1β 
0.000047428 0.000011872 0.000003798 0.000008481 
0.000009125 0.000018260 0.000007943 0.000005611 
0.000012657 0.000271640 0.000007356 0.000016795 
0.000024522 0.000015627 0.000006148 0.000019542 
0.000004533 0.000010244 0.000003815 0.000013035 
0.000007769 0.000029819 0.000003824 0.000012588 
0.000004253 0.000004588 0.000006901 0.000010343 
0.000004599 0.000006851 0.000002560 0.000007872 
10.4 Raw data of histomorphometrical analysis 
Table 10.5: Raw data of total bone-implant contact (BIC) and total bone 
area (BA) 
 
Verum Placebo 
1w 3w 1w 3w 
total BIC 
41.92 62.38 58.86 56.21 
43.21 76.39 49.88 54.05 
51.43 78.94 62.22 67.21 
55.16 74.01 31.32 50.95 
28.42 63.86 42.72 67.49 
36.15 75.57 28.70 62.99 
53.72 60.00 52.03 71.28 
49.48 67.76 20.69 67.00 
23.97 67.10 24.22 59.72 
70.87 63.28 
total BA 
41.85 67.04 56.65 56.14 
56.77 57.57 54.15 38.32 
56.28 62.17 42.90 44.09 
57.22 67.39 51.07 36.90 
51.35 64.09 55.31 38.62 
55.85 72.11 52.30 52.09 
50.47 63.87 57.67 32.10 
63.92 68.20 48.65 41.49 
35.97 66.24 41.88 36.58 
73.27 49.90 
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10.5 Histological evaluation system 
Table 10.6: Histological evaluation system for cell type and response. 
 
Table 10.7: Histological evaluation system for performance response. 
Performance 
Score  
0 1 2 3 4 
Neovascularization 0 
Minimal capillary 
proliferation focal, 
1-3 buds 
 
Groups of 4-7 
capillaries with 
supporting 
fibroblastic 
structures 
Broad band of 
capillaries with 
supporting 
structures 
 
Extensive band of 
capillaries with 
supporting 
fibroblastic 
structures 
Fibrocytes/ 
fibroconnective tissue, 
fibrosis/encapsulation 
0 Narrow band 
Moderately thick 
band 
Thick band Extensive band 
Fatty infiltrate/ 
Bone marrow 
0 
Minimal amount 
of fat associated 
with fibrosis 
Several layers of 
fat and fibrosis 
Elongated and 
broad 
accumulation of fat 
cells around the 
implant site 
Extensive fat 
completely 
surrounding the 
implant 
Osteolysis 0 
Slight extent of 
bone resorption 
Moderate extent 
of bone resorption 
Marked extent of 
bone resorption 
Severe extent of 
bone resorption 
Newly formed bone 0 
Slight extent of 
bone 
formation 
Moderate extent 
of bone formation 
Marked extent of 
bone formation 
Severe extent of 
bone formation 
Cell type/Response 
Score  
0 1 2 3 4 
Polymorphonuclear cells 
(Heterophils) 
0 Rare, 1-5/phfa 5-10/phf Heavy infiltrate Packed 
Lymphocytes 0 Rare, 1-5/phfa 5-10/phf Heavy infiltrate Packed 
Plasma cells 0 Rare, 1-5/phfa 5-10/phf Heavy infiltrate Packed 
Macrophages 0 Rare, 1-5/phfa 5-10/phf Heavy infiltrate Packed 
Giant cells / osteoclastic cells 0 Rare, 1-2/phfa 3-5/phf Heavy infiltrate Sheets 
Necrosis 0 Slight Moderate Marked Severe 
Infection signs 0 Slight Moderate Marked Severe 
Fibrinous exudate (fibrin) 0 Slight Moderate Marked Severe 
Tissue degeneration 0 Slight Moderate Marked Severe 
a
   phf= per high powered (400x) field 
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Osteointegration 
≈ 0% of bone 
to implant 
contact 
1 – 25% 26% - 50% 51% - 75% 76% - 100% 
Osteoblastic cells 0 
Slight = equivalent 
to normal bone 
Moderate, 
>normal bone 
Marked, >> normal 
bone 
Very marked 
Bone density* 0 
Slight = equivalent 
to normal bone 
Moderate, 
>normal bone 
Marked, >> normal 
bone 
Severe, extended 
corticalization or 
packed bone 
Osteoconduction 
≈ 0% bone 
ingrowth/ on 
growth 
1 – 25% 20% - 50% 51% - 76% 76% - 100% 
Material degradation▲ 0 Slight Moderate Marked 
Severe           
(100% degraded) 
Implant migration 
(peripheral 
dissemination/diffusion) 
0 Slight Moderate Marked 
Severe            
(100% 
disseminated) 
Bone remodelling* 
0 (primary 
woven bone) 
Slight (initial signs 
of remodelling) 
Moderate Marked 
Severe (up to 
corticalization) 
▲ compared to previous time point 
* compared to distant normal bone density  
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11 Figure captions 
Figure 2.1: Schematic drawing of bone structure modified from Rahn 
[40]. 5 
Figure 2.2: Overview of the main bone composition. 6 
Figure 2.3: Bone remodelling process by a BMU described by Canalis 
et al. [60]. 9 
Figure 2.4: Overlapping stages of secondary fracture healing: 
hematoma formation (a), fibrocartilaginous callus formation 
(b), bony callus formation (c) and bone remodelling (d). 13 
Figure 2.5: Trabecular bone architecture of normal (a) and osteoporotic 
cancellous bone (b) described by Moritz et al. [131]. 21 
Figure 2.6: Simplified pharmacological action of ZOL in the 
mevalonate pathway. 24 
Figure 4.1: Three-dimensional HPLC plot of ZOL dissolved in water. 33 
Figure 4.2: Experimental setup for the determination of cement 
hardness. 44 
Figure 4.3: Geometric shape of the HydroSet® plug (a), the 
corresponding two-piece moulding systems for 
manufacturing (b) and packaging of sterile implants (c). 47 
Figure 4.4: Principle of crushing strength test for HydroSet® bone 
cement plug. 48 
Figure 4.5: Schematic drawing of sterility test principle. 49 
Figure 4.6: Drilling procedure: 2.1 mm ∅ dental drill (cortex opening) 
(a), 2.5 mm ∅ dental drill (b), bone defect (c), final implant 
position (d), wound closure (e) and after surgery (f). 51 
Figure 4.7: Plug before dissection (a), medial aspect of the tibia before 
trephine drilling (b), trephine drilled sample for qPCR (c) 
and sample for histology (d). 53 
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Figure 4.8: Schematic drawing of histomorphometric evaluation areas. 56 
Figure 4.9: Information from a box- and whisker plot. 57 
Figure 5.1: Light microscopy of LagFix® cylinder (a), HydroSet® 
powder (b) and different sizes of granules: BoneSave® 2-
4 mm (c), BoneSave® 63-90 µm (d), BoneSave® 90-355 µm 
(e) and BoneSave® 355-500 µm (f). 59 
Figure 5.2: Scanning electron microscopy (SEM) of LagFix® cylinder 
(a), BoneSave® granules (b) and HydroSet® powder (c). 60 
Figure 5.3: Particle size distribution of HydroSet® powder. 62 
Figure 5.4: DVS kinetics of LagFix® cylinder (a), BoneSave® granules 
(b) and HydroSet® powder (c). 63 
Figure 5.5: pH value of bone substitute materials after different time 
periods (n = 3; error bars = standard deviation). 64 
Figure 5.6: Three-dimensional plots of different concentrated ZOL 
solutions: 8.44 µg/mL (a), 4.22 µg/mL (b), 2.11 µg/mL (c), 
1.05 µg/mL (d). 65 
Figure 5.7: Time dependent ZOL load (µg/mg) onto bone substitutes 
after dipping in 5 mL of a 2.25x10-4 molar ZOL solution (n 
= 3; error bars = standard deviation). Selected statistically 
significant differences between the material types are 
labeled in the diagram by a line and the corresponding p-
value (n = 9). 67 
Figure 5.8: Time and concentration dependent ZOL adsorption (µg/mg) 
to HydroSet® powder after dipping in 5 mL aqueous 
solution of different ZOL concentrations (n = 3; error bars = 
standard deviation). 68 
Figure 5.9: Loading efficiency (µg/mg) versus surface area (cm²) of 
300 mg BoneSave® fractions (n = 3; error bars = standard 
deviation). 69 
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Figure 5.10: Time and concentration dependent ZOL adsorption (µg) to a 
placebo plug after dipping in 5 mL aqueous solution of 
different ZOL concentrations (n = 3; error bars = standard 
deviation). 70 
Figure 5.11: Cumulative ZOL release (µg/mg) from HydroSet® powder, 
BoneSave® 63-90 µm, BoneSave® 355-500 µm, BoneSave® 
2-4 mm, and LagFix® cylinder (n = 3; error bars = standard 
deviation). Selected statistically significant differences 
between the release profiles of the material types are labeled 
in the diagram by a line and the corresponding p-value (n = 
9). 72 
Figure 5.12: Cumulative ZOL release per surface area (µg/cm2) from 
HydroSet® powder, BoneSave® 63-90 µm, BoneSave® 355-
500 µm, and BoneSave® 2-4 mm (n = 3; error bars = 
standard deviation). 73 
Figure 5.13: Temperature profile of ZOL stability (n = 3; error bars = 
standard deviation). 75 
Figure 5.14: Three-dimensional evaluation of time-dependent ZOL 
stability at a storage temperature of 60°C. 76 
Figure 5.15: ZOL stability stored in glass and plastic at different 
temperatures (n = 3; error bars = standard deviation). 77 
Figure 5.16: 2.25x10-4 mol/L concentrated ZOL solution stored in a 
plastic vial (a) and a glass vial (b) 78 
Figure 5.17: Three-dimensional plots of a 2.25x10-4 mol/L concentrated 
ZOL solution stored for one day at 40°C in plastic (a) and 
glass (b). 79 
Figure 5.18: Light microscopy picture of a lyophilisate containing 20 mg 
mannitol and 100 µg ZOL. 80 
Figure 5.19: Photograph of different lyophilisates containing 100 µg 
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ZOL and 5 mg (1), 10 mg (2), 15 mg (3), 20 mg (4) 
mannitol, 15 mg trehalose (5) or 15 mg sucrose (6). 80 
Figure 5.20: Stability of different ZOL lyophilisates (n = 3; error bars = 
standard deviation). 81 
Figure 5.21: Three-dimensional plots of differently concentrated 
mannitol lyophilisate formulations with 100 µg ZOL 
dissolved in water: 5 mg mannitol (a), 10 mg mannitol (b), 
15 mg mannitol (c) and 20 mg mannitol (d). 82 
Figure 5.22: Cell viability (%) of different concentrated ZOL solutions 
directly dissolved in water (n = 4; error bars = standard 
deviation). 83 
Figure 5.23: pH values of different iso-osmolar ZOL concentrations (a) 
and cell viability (%) of iso-osmolar ZOL solutions (b) (n = 
4; error bars = standard deviation). 84 
Figure 5.24: Cell viability (%) of iso-osmolar ZOL solutions with an 
adjusted pH value of 6.8 (n = 4; error bars = standard 
deviation). 85 
Figure 5.25: Cell viability of release samples from HydroSet® plugs (n = 
4; error bars = standard deviation). 86 
Figure 5.26: HydroSet® powder mixed with different amounts of water: 
pure (a), 20% (b), 25% (c), and 40% (d). 87 
Figure 5.27: Hardness measurements of normal HydroSet® cement (a), 
HydroSet® with 50 µL ZOL solution (b), HydroSet® with 
30% additional water (c) and ZOL loaded and dried 
HydroSet® (d). 89 
Figure 5.28: Crushing strengths of dry and wet HydroSet® verum and 
placebo plugs (n = 3; error bars = standard deviation). 91 
Figure 5.29: SEM images of the plug surface in different magnifications. 92 
Figure 5.30: The 18S (a) and GAPDH (b) ribosomal RNA expression. 93 
Figure captions 
142 
Figure 5.31: Gene expression in rat bone. The total (normalized) relative 
expression levels of bone formation, bone resorption and 
proinflammatory markers (log-scale). 94 
Figure 5.32: Light optical micrograph of an implanted placebo bone 
cement plug after one week. 95 
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